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ABSTRACT 
Tuberculosis is the world’s leading cause of death from a single infective agent. The 
World Health Organisation has declared the disease a “global emergency”. Extra-
pulmonary presentations form a major proportion of new cases, especially since the 
advent of the acquired immunodeficiency syndrome epidemic. Therefore, it is 
important that oral health care workers are aware of tuberculosis in the head and neck 
region and its varied manifestations. This study reports on one hundred and four 
patients diagnosed with tuberculosis and with head and neck tuberculosis lesions.  
 
The aim of the study was to determine the extent to which tuberculosis presents in the 
head and neck region. It was a descriptive, retrospective, record-based study on a 
cohort of tuberculosis patients that presented with head and neck tuberculosis at 
private practices in the Durban area over a fourteen month period. A structured data 
capture sheet was the method chosen for recording the data.  
 
The majority of the sample (89.4%) had tuberculosis of the head and neck lymph 
nodes, five (4.8%) had tuberculosis of the tonsil, two (1.9%) had tuberculosis of the 
larynx, two (1.9%) had tuberculosis of the ear, one (1%) had parotid gland 
tuberculosis and one (1%) had tuberculosis of the nose. The records indicate that 
excision biopsy and histopathological examinations were used to make a diagnosis. A 
third (33.7%) of the patients were confirmed with human immunodeficiency virus 
infection.  
 
A high index of suspicion of tuberculosis is important in the differential diagnosis of 
neck swellings, hoarseness and otorrhoea and in human immunodeficiency virus 
positive patients with an enlarging neck mass. A biopsy is usually necessary for 
diagnosis. Successful outcome depends upon appropriate chemotherapy and timely 
surgical intervention when necessary. Oral health care workers need to be fully 
cognizant of all the various presentations of head and neck tuberculosis to allow early 
diagnosis and quick commencement of appropriate treatment.  
 
Keywords: Head and neck, Tuberculosis, HIV, Oral health care workers, cervical 
lymph nodes, extra-pulmonary. 
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CHAPTER 1: INTRODUCTION 
 
Tuberculosis (TB) is a highly infectious, debilitating disease that typically involves 
the pulmonary system, but can affect any organ or tissue, including the mouth (Randy 
et al. 1993). While TB notification rates continue to decrease in many parts of the 
world, rates have increased more than three-fold in many countries in sub-Saharan 
Africa since 1990, fuelling a 1% increase in global TB incidence (WHO, 2008). In 
1993, it was the world’s leading cause of death from a single infectious agent. The 
World Health Organisation (WHO) declared the disease "a global health emergency" 
(Williams and Jones 1995: 5). In 2005 the African continent, with just 11% of the 
world’s population, accounted for 27% of the global burden of TB and 30% of TB 
related deaths. Over two million new TB cases and over 500 000 TB-related deaths 
are estimated to occur in the region annually (Corbett et al. 2003). Factors that 
influenced the resurgence of the disease included the emergence of multidrug-
resistant (MDR) organisms, social deprivation (injection drug use, homelessness, 
poverty), reduced priority to TB control, the increasing population of young adults 
that constituted the majority of the infected subjects, immigration from endemic areas, 
deteriorating health care infrastructures and the Acquired Immune Deficiency 
Syndrome (AIDS) pandemic. 
 
Every year about 8–10 million people are infected with Mycobacterium tuberculosis 
(M. tuberculosis) and 2 million die from it. About a third of the world's population 
(about 2 billion people) carries the TB bacteria, but most never develop the active 
disease (WHO, 2000). Around 10% of people infected with TB actually develop the 
disease in their lifetime, but this number is increasing due to the human 
immunodeficiency virus (HIV) that severely weakens the human immune system and 
makes people more vulnerable to infections. Disease caused by the relatively non-
virulent non-tuberculosis mycobacteria, such as Mycobacterium avium complex, tends 
to affect only those with very low CD4 lymphocyte counts. In contrast, the risk of TB 
increases after HIV seroconversion and is elevated across the full spectrum of 
immunodeficiency, increasing steeply as the CD4 count declines. 
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The impact of HIV on the TB epidemic is potentially catastrophic: HIV increases the 
susceptibility of the HIV positive person to TB. The advent of HIV has resulted in 5 – 
10% annual risk of developing TB as compared with 5 – 10% lifetime risk of TB 
infection in people without HIV (WHO, 2000). About 50% of TB patients in South 
Africa are infected with HIV (Department of Health (DOH), 2006). HIV-infected 
persons not only have high rates of reactivation TB, but also have heightened 
susceptibility to new exogenous infection and rapidly progressive primary disease. 
Genetic fingerprinting studies have shown that high TB recurrence rates are fuelled by 
a high rate of exogenous reinfection. Nosocomial transmission of TB among HIV-
infected individuals is a major hazard as was illustrated by the recent outbreak of 
extensive drug resistant (XDR) TB in Kwa-Zulu-Natal in 2006 (Andrews et al. 2008). 
 
Tuberculosis infections are acquired by inhalation of the tubercle bacilli that are 
present in airborne particles. TB of the respiratory tract is the most infective form. 
Prior to the HIV epidemic, 85% of reported TB cases were limited to the lungs. This 
has now changed particularly in HIV infected individuals as extra-pulmonary TB 
tends to increase in frequency if immune function is compromised.  
 
With the decrease in the general incidence of head and neck involvement to a point 
where it was often taken as a rare finding, clinicians were not “sensitized” to the head 
and neck manifestations as part of a differential diagnosis. This has often resulted in a 
delay in the diagnosis and therapy or the diagnosis being missed entirely. After a 
decline for several decades, the incidence of mycobacterial disease as a whole, and 
the extra-pulmonary type in particular, is on the rise in many regions of the world. TB 
often presents in the head and neck with the cervical lymph nodes being one of the 
commonest sites of extra-pulmonary TB (Williams and Jones, 1995). Head and neck 
TB also presents in the oral cavity, nose, ears, larynx, thyroid and salivary glands, but 
these locations are rare. 
 
More recently, strains of TB resistant to all major anti-TB drugs have emerged. Drug-
resistant TB is caused by inconsistent or partial treatment, when patients do not take 
their medicines regularly for the required period because they start to feel better, 
because doctors and health workers prescribe the wrong treatment regimens or 
because the drug supply is unreliable. A particularly dangerous form of drug-resistant 
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TB is MDR TB which is resistant to the two most powerful anti-TB drugs, isoniazid 
and rifampicin (Weyer, 2005).  
 
The emergence of XDR TB, especially where many TB patients are also infected with 
HIV is a serious threat to TB control. The Stop TB Strategy was launched by the 
WHO in 2006. The six major components that were included were the (i) Directly 
Observed Treatment, Short-Course (DOTS) expansion and enhancement, (ii) 
addressing TB/HIV, MDR-TB and other challenges, (iii) contributing to health system 
strengthening, (iv) engaging all care providers, (v) empowering patients, and 
communities, and (vi) enabling and promoting research (WHO, 2008).  
 
M. tuberculosis is uniquely hazardous to oral health care workers because of its 
airborne route of transmission. The resurgence of TB as a public heath problem has 
rekindled interest in the disease among oral health care workers. However, much 
research has focused on pulmonary and extra-pulmonary TB (excluding head and 
neck) and there is a paucity of literature on the head and neck region. In some 
instances, systemic symptoms of TB may be absent, and head and neck lesions may 
be the first manifestation of the disease, therefore oral health care workers need to be 
aware of TB in the head and neck region and its varied manifestations.  
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CHAPTER 2: LITERATURE REVIEW 
 
This chapter reviews the literature related to the history of TB in South Africa, its co- 
existence with HIV, the epidemiology, aetiology, pathology and pathogenesis of TB 
and the clinical features of pulmonary disease. It also discusses the presentations in 
the head and neck region. In addition, the diagnosis, risk factors, treatment control 
and prevention are described. The importance of TB to oral health care workers is 
also highlighted.  
 
2.1  BACKGROUND 
 
In the early 1960s, Sir MacFarlane Burnet said, “One can think of the middle of the 
twentieth century as the end of one of the most important social revolutions in history, 
the virtual elimination of the infectious diseases as a significant factor in social life” 
(Burnet, 1962). This was not an uncommon sentiment among the medical community 
and resulted in a decrease in awareness, research, and funding to combat emerging, 
re-emerging and drug resistant infections. Consequently, the medical community was 
ill-prepared when diseases thought to have disappeared, and new diseases, started to 
emerge in the 1980s and 1990s.  
 
In a recent report from the Institute of Medicine (Institute of Medicine, 1992), six 
major factors were identified as contributors to the emergence and re-emergence of 
infectious diseases: (i) changes in human demographics and behaviour, (ii) advances 
in technology and changes in industry practices, (iii) economic development and 
changes in land use patterns, (iv) dramatic increases in volume and speed of 
international travel and commerce, (v) microbial adaptation and change and (vi) 
breakdown in public health capacity required to handle infectious diseases. 
 
Although the number of deaths from infectious diseases had decreased dramatically 
during the twentieth century, there has been an increase from 1980, mainly due to the 
emergence of the HIV (Centres for Disease Control and Prevention (CDC), 1999). 
HIV and other emerging and re-emerging infectious diseases are recognised as 
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significant health hazards and have become the focus of many international and 
national health initiatives.  
Efforts at controlling infectious diseases have addressed sanitation and hygiene, 
vaccination, the use of antibiotics and other antimicrobial medications and improved 
technology in detection and monitoring. Oral health care workers are not excluded 
from these efforts, as many of these endeavours impact directly on dental care. 
 
2.2  TUBERCULOSIS GLOBALLY INCLUDING SOUTH AFRICA 
2.2.1  History  
TB is a widespread scourge that can be traced back to the earliest of centuries. During 
the 17th century, colonialists, settlers and missionaries from Europe and North 
America who were infected with TB arrived in South Africa. They were seeking a 
cure from the sun and fresh air. The previously unexposed and non-immune South 
African population rapidly developed TB (Edginton, 2000).  
 
Workers in the gold mines on the Reef in the 1800s were exposed to silica dust, 
overcrowded hostel living, poor nutritional status and stress, all of which were major 
contributors to the development of TB. They returned to their families in the rural 
areas when they became sick and spread the disease to the community. It was 
estimated that over 60% of the black population of South Africa was infected by 
1930. The rate of active disease in 1953 was measured to be 780 per 100 000 of the 
population of the northern and eastern parts of the country (Edginton, 2000). 
Apartheid policies were responsible for much of the TB manifestations during this 
era. Rural poverty and rapid urbanisation created living conditions that were 
conducive to the continuing epidemic. This was uncontrolled because health services 
were inadequate for the majority of the population. Poorly funded and inadequate 
health services were directly responsible for under-treatment of patients during 
apartheid (Edginton, 2000).  
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2.2.2  Present Situation 
 
TB remains the most important communicable disease in the world and in South 
Africa it accounts for 80% of all notifiable diseases (Edginton, 2000). The annual 
number of new cases averages 380/100 000 population – even in other hard hit parts 
of the world, the average is only about 200 per 100 000.  
 
The TB epidemic in South Africa is one of the worst in the world, with certain 
impoverished areas having the fastest growing epidemic than anywhere else in the 
world. Nearly two thirds of the population in the country are infected with TB, 160 
000 South Africans from all walks of life become ill with TB every year and about 10 
000 people die of TB every year. Poorer communities appear to be at greater risk of 
exposure and to chronic TB infection (DOH, 1996). TB has been common in South 
Africa since colonisation and early urbanization. The notification rate has varied from 
around 50/100 000 in the 1920s, increasing to about 350/100 000 in 1965 followed by 
a decrease until 1988 when the notification rate was 172/100 000. In 2004 the national 
incidence rate was an alarming 718/100 000 – a major increase from 338 per 100 000 
in 1998 (Erstad, 2006). 
 
TB is a major public health problem in South Africa. In 2006, the WHO ranked South 
Africa fifth among the world’s 22 high-burden TB countries (United States Agency 
for International Development (USAID), 2006). The TB epidemic in South Africa is 
likely to be exacerbated over the next few years due to the high prevalence of 
HIV/AIDS. TB-HIV co-infection rates are high, with as many as 60 percent of adult 
TB patients being HIV-positive (USAID, 2006). MDR TB, largely caused by non-
adherence to drug regimens or inappropriate drug regimens, is further exacerbating 
the epidemic. National studies of MDR-TB conducted by the Medical Research 
Council of South Africa in 2002 found that 1.6 percent of new TB cases and 6.7 
percent of re-treatment cases had MDR-TB (USAID, 2006). 
 
The proportion of people with extra-pulmonary TB has also trebled, but appears to 
have stabilised at around 15% (DOH, 2006). Despite a global slowing down in new 
TB cases since 2003, South Africa recorded the world’s second highest rate of new 
cases (incidence rate) in 2006 after Swaziland. The World Health Organisation report 
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in 2006 revealed that 218 people per 100 000 died of TB in South Africa. This was 
more than in any other country in the world (Cullinan, 2008). The problem of TB in 
South Africa is largely a result of historical neglect and poor management systems, 
compounded by the legacy of fragmented health services (Fourie, 2006).  
 
In South Africa, attention has been refocused on the factors associated with the 
observed reversal of previous declining disease trends, transmission modes of M. 
tuberculosis, occupational risk factors and airborne infection control precautions 
(Porteous and Terezhalmy, 2008; CDC, 1998; American Thoracic Society, 1992; 
Bernardo, 1991; CDC, 1991; CDC, 1986). Despite dramatic improvements in public 
health measures associated with M. tuberculosis infection and disease, such as living 
conditions, nutrition and antimicrobial chemotherapy, TB remains a major public 
health problem for much of the world’s population (WHO, 1997; Dolin et al. 1994).  
  
2.2.3    HIV and TB Co-infection 
 
The impact of HIV on the TB epidemic has been catastrophic. HIV increases the 
susceptibility of the HIV positive person to TB. TB is 500 times more common in 
HIV-infected than in the normal population. 80% of affected patients develop extra-
pulmonary disease (Prasad et al. 2007; WHO, 2007; Singh et al. 1998; De Cock et al. 
1992).    
Of the 36 million HIV infected persons in the world, one third are co-infected with M. 
tuberculosis and 75% of these people reside in sub-Saharan Africa (Davidsons, 2002). 
Latent infections present in HIV patients have a 7-10% annual risk of reactivation 
compared to a 5-10% lifetime risk in an HIV uninfected patient. They have a 10-20% 
chance of acquiring TB from an open contact compared to 5-10% in a non-HIV 
patient and a 30-40% chance of developing progressive primary disease as compared 
to 5-10% in a non-HIV individual. More than 60% of HIV infected patients can 
develop disseminated miliary or extra-pulmonary disease compared to less than 25% 
in non-HIV patients. The escalation in TB case rates in sub-Saharan Africa is largely 
attributable to the explosive HIV epidemic. The annual new case (8 million) and death 
(2 million) rates in sub-Saharan Africa are expected to continue to rise (Davidsons, 
2002).  
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HIV critically impairs cell-mediated host responses to M. tuberculosis. In the immune 
system, CD4 lymphocytes defend the body against TB. Examination of 
bronchoalveolar lavage fluid from tuberculous lung segments in HIV infected patients 
reveals failure of recruitment and activation of CD4 lymphocytes (Lawn et al. 2002). 
Numeric depletion and functional impairment of these cells and disruption of CD4 
lymphocyte macrophage interactions result in impaired granuloma formation and 
reduces the immune systems ability to prevent the growth and spread of M. 
tuberculosis. A weakened immune system allows for dissemination of the bacteria to 
areas other than the lungs, which explains the increased likelihood of extra-pulmonary 
TB among HIV positive individuals (Achmat and Roberts, 2005). At the recent 
conference of the Parasitological Society of Southern Africa it was found that the 
probable link between AIDS and TB could be the results of chronic infection by the 
helminths worm that downregulates the cellular immune response that is needed to 
prevent infection by the HIV and M. tuberculosis. It was demonstrated that prevention 
of helminthiasis could be part of the solution to the pandemics of HIV/AIDS and TB 
(Fincham, 2008).  
Radiographic appearances of pulmonary TB in patients with HIV co-infection reflect 
impairment of the host inflammatory response, with reduced likelihood of cavitation, 
fibrosis and classical apical disease. Normal chest radiographs are found in 
approximately 5% of patients with smear positive pulmonary TB. Mediastinal 
lympadenopathy and non-specific patterns of consolidation are more common 
(Harries, 1990).  
Diagnosis is made by mycobacterial culture of blood, bone marrow or tissue in 
patients with late stage HIV and low CD4 counts. Quadruple anti-TB combination 
therapy has a good response. Patients presenting with both HIV infection and TB may 
have typical clinical and radiographic features of TB. Experienced clinicians in 
central Africa have noticed a change in the pattern of the disease. Patients produce no 
sputum or have negative sputum smears, little change in chest radiography, or there 
may be diffuse pulmonary infiltrates without cavitation. Extra-pulmonary disease 
appears to be more common – especially in forms where they were previously 
uncommon (Harries, 1990).  
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The change in disease pattern has made diagnosis of TB more difficult (Singh et al. 
1998; Harries, 1990). Extra-pulmonary TB can be difficult to diagnose and 
differentiation from neoplastic or other inflammatory conditions can be difficult, 
particularly in mucosal TB involving the larynx, hypopharynx and nasopharynx 
(Choudhury et al. 2005). In view of the high frequency of non-cavitatory pulmonary 
disease and extrapulmonary forms of TB, sputum smear microscopy has a low 
sensitivity for diagnosis. Sensitivity is substantially increased by sputum culture, but 
this is slow and expensive and the necessary infrastructure is not available over much 
of Africa (Lawn et al. 2002). 
HIV in the mid-1980s was not a problem in South Africa and the impending threat to 
the population was largely ignored (Edginton, 2000; WHO, 2000). Reported cases of 
TB have quadrupled in South Africa since 1988. The prevalence of HIV in South 
Africa has increased. The proportion of TB in women has increased from 34.9% in 
1995 to 43.5% in 2004. As a result of HIV the proportion of TB patients with extra-
pulmonary TB is high at 16.1%. The prevalence of HIV in TB patients was 55.3% 
(WHO, 2005).  
As a result of the HIV epidemic in South Africa, Anti-retroviral treatment (ART) has 
been made available in the public sector. Irrespective of whether they are receiving 
anti-retrovirals (ARVs), people with HIV are more vulnerable to developing TB 
(DOH, 2000). The progression of HIV is also hastened by TB. There is no 
standardised recording and reporting system in place in South Africa for HIV, which 
has resulted in slow progress in the HIV/TB collaboration, therefore assessing the 
TB/HIV collaboration is problematic.   
TB, which can occur at any time during the course of HIV, most often occurs early in 
the disease and probably accelerates the progression of HIV disease. The WHO 
DOTS strategy remains the central component of global TB control strategies. 
However, while successful in low HIV prevalence settings, this strategy alone has 
proven insufficient to contain the African TB epidemic in high HIV prevalence 
countries.  
Additional strategies are needed, including intensified or active case-finding in patient 
populations at high risk of TB, TB preventive therapy (isoniazid prophylaxis for six 
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months) can be used in HIV positive patients who have positive tuberculin skin tests 
and who are not already sick with TB (DOH, 2000) and TB patients should receive 
HIV information and education and should be offered HIV counselling and testing. 
Ultimately, control of the HIV epidemic is needed to stem the TB epidemic in 
countries in southern Africa. 
2.2.4  Epidemiology 
TB remains the most common cause of death from a single microbial agent and is the 
most common infectious disease in the world. In 1993, TB was resurrected as a major 
public health problem world-wide after two decades of neglect and the WHO declared 
TB to be "a global health emergency" (Williams and Jones 1995: 5). In 2006, 9.2 
million new cases (139 per 100 000 population) and 1.7 million deaths from TB 
occurred globally, of which 0.7 million cases and 0.2 million deaths were HIV 
positive people. TB is a major cause of illness and death especially in Asia and 
Africa. South Africa ranks fourth in terms of absolute number of cases. The African 
region has the highest incidence rate per capita (363 per 100 000 population) (WHO, 
2008). 
 
The falling global incidence reversed in the mid 1980s in developed and developing 
nations. The reason for the increasing incidence of pulmonary TB in developed 
countries was due to HIV (mainly urban), immigration from high prevalence areas, 
increasing life expectancy of the elderly, social deprivation (injection drug use, 
homelessness, poverty), drug resistance (MDR-TB) and reduced priority for TB 
control. In developing countries the increase in incidence was due to HIV (mainly 
urban), population increase, lack of access to health care, poverty, civil unrest 
ineffective control programmes and drug resistance (MDR-TB) (Davidsons, 2002). 
The most serious aspect of the TB epidemic is the emergence of MDR-TB. It is TB 
that is resistant to at least isoniazid and rifampicin and it is difficult and expensive to 
treat (Weyer, 2005). The cure rate of MDR-TB is currently less than 50% and it is 
therefore essential to prevent its development. MDR-TB is the consequence of human 
error in prescription of chemotherapy, management of drug supply, patient 
management and patient compliance.  
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Health care workers can reduce the threat of MDR by prescribing the correct TB 
drugs in the correct dose for new TB patients, ensure that the patients adhere to 
treatment through DOTS and promptly detect and investigate any TB patient who 
fails to respond to TB drugs (DOH, 2000). Patients with active, untreated MDR-TB 
can infect large numbers of HIV-positive individuals, leading to outbreaks of MDR-
TB with high case-fatality rates. It is therefore important that MDR-TB be prevented 
by rigorous adherence to the principles of the TB Control Programme (the DOTS 
strategy) and by patiently and consistently building partnerships with patients, their 
families and communities to cure tuberculosis at the first attempt (Weyer, 2005). 
Since the mid-eighties, patients with MDR-TB have been diagnosed in each of the 
nine provinces in South Africa, and a recent national survey by the Medical Research 
Council indicated a rate of 1.6% MDR in new TB cases and 6.6% in previously 
treated cases. This translates into at least 6 000 new cases of MDR-TB in South 
Africa each year (DOH, 2004). For this reason the DOTS-Plus strategy (which is an 
integrated approach to the management of TB and MDR-TB) was implemented in 
South Africa for the management of MDR-TB.  
  
Nosocomially acquired MDR-TB presented a serious public health problem in the 
early 1990s initially in the United States of America and then in the Southern 
European countries (Davidsons, 2002). MDR-TB is at critical levels in specific 
regions of the world and limited to localised epidemics. DOTS has been adopted to 
prevent the generation of resistant strains and to carefully introduce second-line drugs 
to treat patients with MDR (Espinal, 2003). XDR-TB has emerged recently as a 
serious threat to TB control. XDR-TB is resistant to isoniazid, rifampin and any 
fluoroquinolone and at least one of three injectable second-line drugs (amikacin, 
kanamycin or capreomycin) (Mori, 2007). Several factors are implicated in the 
increased risk of individuals developing TB. Patient related factors are age (children 
more than young adults), first-generation immigrants from high prevalence countries, 
close contact of patients with smear – positive pulmonary TB, chest radiograph 
evidence of self-healed TB and primary infection less than one year previously.  
Associated diseases that increase the risk of TB are HIV, silicosis, immuno-
compromised states, malignancy (especially lymphoma and leukaemia), Type 1 
diabetes mellitus, chronic renal failure and gastrointestinal disease associated with 
malnutrition (Davidsons, 2002).  
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2.3  AETIOLOGY 
TB is a highly infectious, debilitating disease that commonly involves the pulmonary 
system, lymph nodes, soft tissue or skin including the mouth (Davidsons, 2002; 
Randy et al. 1993). The genus Mycobacterium contains a variety of species, ranging 
from human pathogens to relatively harmless organisms. As a major cause of TB, M. 
tuberculosis is by far the most historically prominent member of this group of 
bacteria. The subtypes of Mycobacteria involved in infections of the head and neck 
are divided into two major categories: M. tuberculosis and atypical Mycobacteria.  
The atypical are opportunistic and usually cause infection in patients with weak 
immunologic defences, such as young children and immuno-compromised patients 
(Munck and Mandpe, 2003).  In addition to their very slow growth on special 
enriched media, these aerobic slender rods are characterised by their acid-fast staining 
features. The unusually high lipid content of the cell wall confers the organisms with 
the ability to strongly retain the red dye (carbolfuchsin) after treatment with an acid-
alcohol solution. This unique structure also allows the bacteria to survive outside a 
host’s body, suspended in airborne micro droplet nuclei for extended periods of time. 
 
Contrary to myth, M. tuberculosis is not a highly contagious bacterium. It does not 
synthesise potent exotoxins or extra cellular enzymes, and it is not surrounded by an 
antiphagocytic capsule. Onset of infection appears to be related to the ability of the 
tubercle bacilli to multiply within the host cells and tissues while at the same time 
resisting host defences. Infection with M. tuberculosis typically requires prolonged 
close contact of a susceptible host with an infectious source. The closeness of contact 
with aerosol bacilli and the degree of infectivity of the mycobacterial source are the 
most important considerations for infection (Davidsons, 2002). 
The overwhelming majority of primary human infection involves the inhalation of 
mycobacteria-laden respiratory micro-droplets (CDC, 1994; Bates and Stead, 1993). 
When a person has active pulmonary TB (the most common form of TB) they cough 
up very small infectious particles that can remain in the air for long periods. These 
particles, called “droplet nuclei”, when inhaled, can establish an infection in the 
lungs. The diameter of the aerosol droplets range from 1 to 5 microns. Dispersal of 
M. tuberculosis occurs via these droplets as a result of coughing, sneezing or even 
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speaking. Micro-droplet nuclei are small enough to bypass protective host bronchial 
mucocilliary defences, leading to mycobacteria subsequently replicating in both free 
alveolar spaces and within phagocytic cells.  
Repeated prolonged exposure to air that has been contaminated by the droplets from a 
person with TB predisposes others to infection. People living in the same home as an 
infected individual, or close friends or co-workers, who routinely breathe the same 
mycobacteria-contaminated air from an undiagnosed or untreated person with 
pulmonary TB, have a high risk of acquiring TB (Davidsons, 2002).  
 
Transmission is most common indoors in overcrowded and poor housing conditions 
since direct sunlight can kill these infectious particles. A person's risk of exposure is 
determined by the concentration of droplet nuclei in the air and the length of time a 
person is exposed to the air. TB can occur in areas other than the lungs, such as in the 
lymph nodes, central nervous system, and the gastro-intestinal tract. This is referred to 
as extra-pulmonary TB and is most common in HIV positive people, infants and 
children (Achmat and Roberts, 2005). Extra-pulmonary TB, which is rarely 
infectious, has dramatically increased. It occurs in 15% of all patients with TB and in 
70% of patients with AIDS and TB.  
 
Extra-pulmonary TB represents a diagnostic challenge and is usually diagnosed by 
specialists in the involved anatomic area (Goguen and Karmody, 1995). Onset of 
clinical disease is characterised by gradual infiltration of neutrophils, macrophages 
and T lymphocytes. Distinctive granulomatous TB lesions called tubercles may 
appear anywhere in the lung parenchyma; however, they are most evident in the 
periphery. The immunocompetence of the affected host plays a significant role in 
controlling the extent and severity of resultant disease (Ellner, 1997; Orme et al. 
1993). Most people infected with M. tuberculosis develop a positive type IV 
hypersensitive skin test reaction. Once infected with the bacteria, it remains dormant 
for many years (latent TB) because a properly working immune system is capable of 
suppressing the infection and preventing the bacteria from multiplying. When the 
immune system is weakened for example by HIV or poor nutrition, the bacteria begin 
to multiply and this often leads to active TB. The vast majority (90%) of HIV 
negative people infected with M. tuberculosis never develop TB. For those infected 
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individuals who develop clinical symptoms, fatigue, malaise, weight loss, night 
sweats and fever are common signs, in addition to positive chest radiographic 
manifestations.  
 
2.4  PATHOLOGY AND PATHOGENESIS 
Initial mycobacterial infection may progress to several different states depending on 
the extent of M. tuberculosis exposure and resistance of the patient. These include (i) 
asymptomatic primary tuberculosis, (ii) symptomatic primary tuberculosis, (iii) 
progressive primary tuberculosis and (iv) re-activation tuberculosis (Davidsons, 
2002). 
A major risk factor for the progression of initial infection with tubercle bacilli to 
more severe disease stages is the absence of an adequate host acquired cellular 
immune response to mycobacterial antigens. The ability of an infected individual to 
develop dual cellular and humoral immune responses against M. tuberculosis 
antigens thus greatly influences disease onset and progression. 
Asymptomatic primary tuberculosis: Individuals may be infected with M. 
tuberculosis without apparent clinical manifestations. When the skin is tested, 
individuals with asymptomatic primary tuberculosis display a positive tuberculin test 
reaction indicating that they have been infected and have developed cell-mediated 
immunity against the bacteria. This protective immune response prevents the 
continued multiplication and dissemination of the bacteria, but it does not destroy all 
of the bacteria present. The remaining bacteria are sequestered within the tubercles in 
the affected tissues and may be the source of bacteria that initiate reactivation 
tuberculosis (Davidsons, 2002). 
Symptomatic primary tuberculosis: In symptomatic primary tuberculosis, M. 
tuberculosis is spread via the lymphatics, to cause granulomatous inflammation in 
the lung periphery and hilar nodes, and is accompanied by respiratory symptoms. 
The tonsil, intestine or skin may also be the site of primary disease (Davidsons, 
2002).  
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A small sub pleural lesion (the Ghon focus) develops following inhalation with M. 
tuberculosis. Bacilli are rapidly transported to the regional (hilar) lymph nodes and 
the primary complex develops. Activated macrophages that have ingested the bacilli 
aggregate and the lesions enlarge. Two T cell-mediated immune responses start at 2-
4 weeks. The non-activated macrophages containing bacilli are destroyed by a 
delayed-type hypersensitivity reaction which also results in tissue necrosis and 
caseation. Macrophages are activated into epitheloid cells with formation of 
granulomas at the periphery of the caseation. The primary complex heals 
spontaneously in 1-2 months in 85-90% of cases and the tuberculin skin test becomes 
positive (Davidsons, 2002).  
Progressive primary tuberculosis: A much more serious disease may develop in 
those individuals who are less resistant to the tubercle bacilli. Multiplication of M. 
tuberculosis is not contained in 10-15% of cases and lymph node enlargement results 
in either local pressure effects, lymphatic spread to the pleura or pericardium, or 
rupture into an adjacent bronchus or pulmonary blood vessel. Micro-organisms may 
spread throughout the body either (i) by means of the blood resulting in miliary 
tuberculosis, (ii) via the respiratory tissues, inducing bronchopneumonia or (iii) 
throughout the gastro-intestinal tract as a result of organisms being coughed up and 
swallowed (Davidsons, 2002). In miliary tuberculosis, foci of infection occur in 
distant organs and tissues but most frequently develop in the meninges, lungs, liver 
and renal cortex. Although cell-mediated immunity may develop in some patients, 
others may not react (anergy) when the skin is tested with tuberculin protein 
preparations. Anergic patients have a poor prognosis for recovery and often die 
without rapid treatment (Davidsons, 2002). 
Reactivation tuberculosis: Reactivation tuberculosis occurs in individuals who have 
developed primary tuberculosis and who are asymptomatic, but who still carry the 
bacteria within tubercles. Of these patients, 5-10% reactivates during their lifetime 
resulting in post primary diseases, which are predominantly pulmonary (75%) and 
infectious (50% smear-positive). Reactivation of disease is thought to be due to the 
activation of persistent bacteria in the tubercles of previous infection that become 
activated by some alteration in host resistance (Davidsons, 2002).   
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Infection is characterised by tubercle formation, caseation, fibrosis and further 
extension of the lesion. Progression may advance into a bronchus, leading to 
cavitation of the lung and secretion of infectious sputum. Infection after exposure, 
development of progressive primary disease and re-infection from other infectious 
cases are all increased in HIV-infected individuals. In the presence of good immune 
function in HIV patients, clinical disease resembles classical post-primary TB. In 
patients where significant immunodeficiency has occurred, the presentation is either 
disseminated or extra-pulmonary. There are reduced smear-positive rates in 
pulmonary TB, less cavitation, atypical chest radiograph, increased disseminated 
disease, more extra-pulmonary infection and greater risk of adverse drug reactions in 
HIV patients (Davidsons, 2002). 
 
2.5  CLINICAL FEATURES OF PULMONARY DISEASE 
Primary pulmonary TB usually occurs in childhood and is generally asymptomatic – 
patients may develop a febrile illness. Erythema nodosum may present with primary 
TB and is associated with a positive tuberculin skin test. Progressive primary disease 
may appear during the course of the initial illness or after a latent interval of weeks 
or months. Features depend on the site affected.  
Miliary TB is a severe infection that is often diagnosed late. It may start suddenly or 
there may be a period of 2-3 weeks when fever, night sweats, anorexia, weight loss 
and a dry cough are present. A headache may indicate co-existence with TB 
meningitis. Lesions (resembling millet seeds) are found throughout the lungs and 
anaemia and leucopenia may be present.   
Post-primary pulmonary TB in adults is a sub-acute illness characterised by cough, 
haemoptysis, dyspnoea, anorexia and weight loss associated with fevers and night 
sweats. Earliest radiological change is an ill-defined opacity situated in one of the 
upper lobes. Two or more areas of the lung may be involved and it may be bilateral. 
As the disease progresses, consolidation, collapse and cavitation develop. Collapse 
may be marked in extensive disease and this could result in displacement of the 
trachea and mediastinum. Draining of a caseous lymph node into an adjoining 
bronchus may result in tuberculous pneumonia (Davidsons, 2002). 
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2.6  CLINICAL FEATURES OF EXTRA-PULMONARY DISEASE 
Lymph nodes are the most common extra-pulmonary site of disease. The most 
frequently affected glands are the cervical and the mediastinal followed by the 
axillary and inguinal. The nodes are initially mobile and painless and then become 
matted. With caseation and liquefaction, the swelling becomes fluctuant and may 
discharge through the skin with the formation of a “collar-stud” abscess and sinus 
formation. Fevers and night sweats are not frequently present and the tuberculin skin 
test is usually positive. Enlargement, development of new nodes and suppuration 
may occur during or after treatment without evidence of continued infection and 
surgical excision is rarely necessary (Davidsons, 2002). 
Gastrointestinal TB patients present with a wide range of signs and symptoms. Upper 
tract involvement is rare. Prominent features include fever, night sweats, anorexia 
and weight loss. Pericardial disease occurs in two main forms – pericardial effusion 
and constrictive pericarditis. Presentation is usually insidious (Davidsons, 2002). 
Meningeal disease is the most important form of Central nervous system disease. 
This can be life-threatening and fatal if not diagnosed early. TB of the spine involves 
the lower thoracic and lumbar spine and usually presents with chronic back pain. TB 
can affect any joint, but most frequently involves the hip or knee. Pain and swelling 
is usually present and fever and night sweats are uncommon. Reduction in joint 
space and erosions appear as the disease progresses. 
In Genitourinary disease patients are mildly symptomatic for many years. 
Haematuria, frequency and dysuria are often present (Davidsons, 2002). 
 
2.7  HEAD AND NECK MANIFESTATIONS OF TB 
 
Head and neck TB can present in many forms depending on the site of involvement, 
the stage of the disease and the immune status of the patient (Al-Serhani, 2001). 
Head and neck TB forms nearly 10% of all extra-pulmonary manifestations of the 
disease.  
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Extra-pulmonary presentations form a major proportion of new cases, especially 
since the advent of the AIDS epidemic. Therefore oral health professionals need to 
be aware of TB in the head and neck region and its varied manifestations (Prasad et 
al. 2007). The cervical lymph nodes are one of the commonest sites of extra-
pulmonary TB. Other sites include the oral cavity, nose, ears, larynx, pharynx, 
thyroid, salivary glands, eye, cervical spine and mandible (Menon et al. 2007).  
 
2.7.1  Cervical Lymph Nodes 
 
The cervical lymph nodes are the most common site in the head and neck region to be 
affected by TB (Nohrstrom et al. 2007; Prasad et al. 2007; Munck and Mandpe, 
2003). The presentation could be an isolated, discreet, affected node or the more 
common collection of matted nodes (Munck and Mandpe, 2003). The upper deep 
cervical nodes are commonly involved with matting, ulceration and abscess formation 
(Prasad et al. 2007). A fluctuant mass is present in 10% of patients and a draining 
sinus is present in 5% of patients. Skin overlying the lesion may appear erythemic and 
may be tender to palpation. The clinical course and treatment are different for 
tuberculous and non-tuberculous mycobacteria, therefore it is important to 
differentiate between masses caused by them. The posterior and supraclavicular 
lymph nodes are involved with tuberculous mycobacterial infections. Nontuberculous 
mycobacterial infections involve submandibular and submental cervical lymph node 
groups. These infections are generally seen in children between the ages of 1 and 5 
and in immunocompromised patients. Constitutional symptoms are rare and chest x-
rays are negative for signs of pulmonary TB (Munck and Mandpe, 2003).    
 
The incidence of tonsillar, submandibular and submental lymph nodes affected by M. 
tuberculosis could be as high as 10% of cases of pulmonary TB. The consistency of 
nodules varies with the stage of disease. A clinical classification by Hooper states that 
in Stage 1 the nodes are enlarged, firm, mobile, discrete and slightly tender showing 
non-specific reactive hyperplasia. In Stage 2 the nodes are larger, rubbery and fixed to 
surrounding tissues because of periadenitis with caseation. In Stage 3 there is central 
abscess formation, Stage 4 collar-stud abscess formation and Stage 5 sinus formation 
(Ishikawa et al. 1982).  
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Treatment in the management of peripheral node TB includes surgical incision with 
chemotherapy, chemotherapy first and then surgery or chemotherapy alone with anti-
tubercular drugs for varying durations (Williams and Jones, 1995; Subrahmanyam, 
1993). 
 
2.7.2 Larynx 
 
There are two theories that attempt to explain the infectious route of laryngeal TB. 
The bronchogenic theory states that the larynx is infected by direct spread of large 
numbers of bacilli from the endobronchial tree while the hematogenous theory 
suggests that the larynx becomes involved through the hematogenous route from other 
distant primaries rather than direct spread from the airway.  
 
The bronchogenic mode of transmission is more common therefore a chest x-ray 
examination should be emphasized (Wang et al. 2009; Wang et al. 2007). Laryngeal 
TB is rare occurring in less than 1% of TB cases. Hoarseness is the most common 
symptom. Patients may also describe odynophagia, dysphagia, cough, otalgia and 
signs of stridor (Wang et al. 2009; Wang et al. 2007; Lim et al. 2006; Nalini and 
Vinayak, 2006; Munck and Mandpe, 2003; Rinaggio, 2003; Yencha et al. 2000; 
Kandiloros et al. 1997; Williams and Jones, 1995; Rupa and Bhanu, 1989; Levenson 
et al. 1984). The vocal folds (true followed by the false) are the most common site 
and make up 50-70%, closely followed by the ventricular bands, which make up 40-
50% of cases. The epiglottis, aryepiglottic fold, arytenoid, posterior commissure and 
subglottis make up 10-15% of cases. The anterior half of the larynx is affected twice 
as often as the posterior half (Williams and Jones, 1995).   
 
Clinical features in laryngeal TB vary from ulcers on the true vocal folds to 
hypertrophic nodules and hyperaemia and oedema of the arythenoids and aryepiglottic 
folds. Broad based exophytic lesions without significant erythema and oedema may 
also be seen (Prasad et al. 2007; Lim et al. 2006; Yencha et al. 2000; Levenson et al. 
1984). Histopathological examination must be done to differentiate between cancer 
and laryngeal TB (Munck and Mandpe, 2003; Yencha et al. 2000; Williams and 
Jones. 1995). Patients with laryngeal TB are treated with anti-tuberculin medications 
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and demonstrate a quick clinical response and rarely require a tracheotomy to secure 
the airway (Munck and Mandpe, 2003; Williams and Jones, 1995).  
 
2.7.3  Nasal 
 
Nasal TB is rare. The English literature has reported 26 cases during the twentieth 
century. It is caused either by a primary infection or pulmonary disease (Goguen and 
Karmody, 1995).  Rarity is the result of the nasal mucosa being resistant to the M. 
tuberculosis. Common sites of involvement are the cartilaginous septum and the 
inferior turbinate. The lesions may present as ulcerated, infiltrative or polypoidal. The 
lesions of the paranasal sinuses present as pale, polypoidal mucosa of the maxillary 
anthrum or multiple polyps of the ethmoid. Bone involvement with fistula formation 
is rare (Prasad et al. 2007; Williams and Jones, 1995). TB of the nasal cavity is 
painless and causes nasal obstruction and catarrh (Williams and Jones, 1995). 
Treatment for nasal TB is varied. Surgical excision, diathermy, cautery, lactic acid 
application and radium treatments were the early regimens. There could be recurrence 
with surgical excision. Since 1951 reported cases have been treated with anti-TB 
medications and no recurrences have occurred (Goguen and Karmody, 1995).  
 
 
2.7.4  Oral Cavity  
 
Less than 3% of the cases involve the oral cavity (Molinari and Chandrasekar, 1991; 
Mani, 1985). The bacteria can infect oral tissues and lymph nodes. Within the oral 
cavity, lesions occur in the soft tissues and supporting bone and in tooth extraction 
sites, and the tongue and floor of the mouth. They occur in the following order – 
tongue tip, tongue border and floor of the mouth, soft palate anterior tonsillar pillar 
and uvula and dorsum and base of the tongue. Oral lesions appear as painful ulcers, 
nodules, fissures and tuberculosis granulomas (Tovaru et al. 2008; Prasad et al. 2007; 
Ajay et al. 2006; Feller et al, 2005; Miziara, 2005; Rinaggio, 2003; Von Arx and 
Husain, 2001; Eng et al. 1996; Dimitrakopoulos et al. 1991; Hashimoto and Tanioka, 
1989; Waldman, 1982; Prabhu et al. 1978; Rauch and Friedman, 1978). The 
tuberculosis oral ulcerations may be solitary or multiple, occasionally painful and 
usually involves the dorsum of the tongue. The mature ulcer has an irregular outline 
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and a rough or granular surface. The surrounding mucosa is erythematous and 
oedematous.   
 
The infection in the oral cavity requires mucosal injury and could result from 
pulmonary disease. The gingival, dental sockets and buccal folds are commonly 
involved by direct inoculation. These lesions can be distinguished from carcinoma by 
histological examination (Tovaru et al. 2008; Ajay et al. 2006; Feller et al, 2005; 
Miziara, 2005; Munck and Mandpe, 2003; Von Arx and Husain, 2001; Eng et al. 
1996; Williams and Jones, 1995; Hashimoto and Tanioka, 1989; Verma et al. 1989; 
Waldman, 1982; Prabhu et al. 1978; Rauch and Friedman, 1978; Brennan and Vrabec, 
1970).  
 
Primary tuberculosis lesions of the mouth which are seen in younger patients are 
generally painless and there may be regional lymphadenopathy present. When they 
become secondarily infected with bacteria from the oral cavity, they may become 
painful. Secondary TB is more common among older patients and is usually a 
complication of pulmonary disease (Tovaru et al. 2008; Miziara, 2005; Iype et al. 
2001; Hashimoto and Tanioka, 1989; Mani, 1985; Waldman, 1982). Tongue lesions 
are usually painful, grayish yellow, firm and well demarcated. Gingivitis tuberculous 
presents as irregular, nodular lesions that may cause more diffuse involvement (Ajay 
et al. 2006; Iype et al. 2001; Waldman, 1982).  
 
TB of the oral cavity has become a forgotten diagnosis of oral lesions because of its 
rarity. With the recent reversal in the incidence of TB it should always be included in 
the differential diagnosis of oral ulcerations as a delay in the diagnosis may have 
serious consequences (Tovaru et al. 2008; Ajay et al. 2006; Von Arx and Husain, 
2001). Chemotherapy is used to treat TB of the oral cavity (Williams and Jones, 
1995). 
 
2.7.5  Jaws 
 
TB of the mandible and tempro-mandibular joint (TMJ) is rare. The incidence does 
not exceed 1.4% of all patients affected by the disease. Young patients with 
pulmonary involvement can present with TB of the mandible. TMJ TB can be a 
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primary infection or a fistulous communication from TB otitis media. Trismus and a 
painful fluctuant swelling in front of the ear are the symptoms experienced (Prasad et 
al. 2007). 
TB of the jaws is manifested as a tuberculous granuloma or tuberculous osteomyelitis. 
Radiographically the tuberculous granuloma presents as a periapical radiolucency 
involving a nonvital tooth. Pain and swelling of the affected area is present. The 
swelling later softens and ruptures intra-orally or extra-orally. Sinus tracts are then 
present and trismus occurs when the mandible is affected (Mavropoulou and 
Yannoulopoulos, 1986). The spread of infection may occur through an extraction 
socket, mucosal tear associated with an erupting tooth, regional extension of a soft 
tissue lesion to underlying bone, or by haematogeneous spread. Apical osteitis, 
periodontitis with horizontal bone loss or a widespread destructive osteolytic lesion 
are some of the presentations. It may be mistaken for a dental abscess in the absence 
of systemic symptoms (Bhatt and Jayakrishnan, 2001). Patient recovers with anti-
tuberculous treatment. In tuberculous osteomyelitis complete drainage of the abscess 
and removal of necrotic bone is done in combination with anti-tuberculous 
chemotherapy. Although TB rarely affects the jaws, it should be considered in 
differential diagnosis of chronic joint disease since this disease continues to be a 
health problem in both developed and underdeveloped countries (Dinkar and 
Prabhudessai, 2008; Soman and Davies, 2003; Bhatt and Jayakrishnan, 2001; 
Mavropoulou and Yannoulopoulos, 1986). 
 
2.7.6  Cervical Spine 
 
TB of the cervical spine occurs more often in prepubertal children than in adults. The 
commonest symptom of TB cervical spine is pain followed by dysphagia, dyspnoea 
and stridor due to pressure effects. Abscess formation presents as a retropharyngeal 
abscess, sternomastoid abscess or parotid mass (Prasad et al. 2007; Williams and 
Jones, 1995). Surgery is performed on large abscesses (Williams and Jones, 1995). 
 
2.7.7  Aural  
 
TB affecting the middle ear cleft has dramatically decreased over the past forty to 
fifty years. This could be due to the availability of specific bactericidal anti-
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tuberculous drugs, improvement in the public health services, massive inoculation of 
cattle with the virtual eradication of Bovine-strain TB, improvement in housing and 
widespread Bacille Calmette-Guérin (BCG) inoculation campaigns directed at babies 
and children of school age (Ramages and Gertler, 1985).   
 
Aural TB is usually found in children and young adults. Typical features are painless 
otorrhoea, central perforation, pale middle-ear granulations, severe hearing loss and 
facial paralysis. Bone necrosis and sequestration in the mastoid is commonly found. 
With superimposed infection there may be otalgia, foul-smelling infection, acute 
mastoid infection and fistulisation (Prasad et al. 2007; Vaamonde et al. 2004; Munck 
and Mandpe, 2003; Lee and Schecter, 1995; Williams and Jones, 1995; Yaniv, 1987; 
Ramages and Gertler, 1985). Multidrug therapy is the treatment of choice while 
awaiting culture and sensitivity results for more targeted therapy. Surgical 
intervention is carried out on patients with facial paralysis, subperiosteal abscess 
formation, fistulisation, labyrinthitis, intracranial complications and progressive 
disease recalcitrant to medical therapy (Munck and Mandpe, 2003; Williams and 
Jones, 1995; Ramages and Gertler, 1985). 
 
TB osteomastoiditis is a rare complication of TB today. When it occurs it may cause 
significant morbidity. Diagnosis is difficult if the patient shows no other 
manifestations of the disease and may be delayed for months or years, since most 
physicians are not familiar with the typical presenting features (Pavlopoulou et al. 
2000).   
 
2.7.8  Salivary Glands 
 
TB of the salivary glands is rare and only about a hundred cases have been reported in 
the world wide literature. It can be central, with involvement of the inter-glandular 
lymph nodes, or diffuse, with involvement of the parenchyma. Parotid involvement 
presents as a firm, non-tender mass. Abscess formation and fistulisation may also 
occur. Seventh nerve palsy is rarely seen (Prasad et al. 2007). The parotid gland is the 
most commonly involved followed by the submandibular and then sublingual gland. 
In the parotid the infection arises in the intra-parotid lymph nodes the bacilli reaching 
the gland either via the duct or through the lymphatic channels.  
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Patients are generally well with no evidence of pulmonary involvement therefore TB 
infection is often indistinguishable from neoplasm. Pain manifests later and facial 
palsy is rare (Williams and Jones, 1995). Anti-tuberculosis chemotherapy is the 
standard treatment. Surgical intervention is avoided in these patients (Munck and 
Mandpe, 2003; Williams and Jones, 1995). TB of the salivary gland should always be 
included in the differential diagnosis of salivary gland tumour especially in the areas 
where TB is endemic. This would avoid unnecessary surgery for histological 
confirmation and anti-tuberculous medication would be sufficient to resolve the 
condition. Therefore the combination of fine needle aspiration cytology and molecular 
biology methods such as polymerase chain reaction should be used as initial 
diagnostic tools for the diagnosis of salivary gland TB (Kim et al. 2005). 
 
2.7.9  Pharynx 
 
Pharyngeal infection is slowly progressive and presents as a chronic nodular 
irregularity of mucosal surfaces. The two main sites of pharyngeal involvement are 
the nasopharynx and oropharynx. These are mostly primary infections. Nasal 
obstruction with rhinorrhea is the most common complaint. Cervical 
lymphadenopathy may accompany nasopharyngeal TB. Ulcerations and fibrosis of the 
tonsils make it difficult to distinguish between tonsillar TB and tonsillar carcinoma 
(Munck and Mandpe, 2003; Williams and Jones, 1995). Treatment with 
chemotherapy shows rapid improvement (Williams and Jones, 1995). 
 
2.7.10    Eye 
 
TB of the eye is rare and is found in about 1.4% of hospitalized patients. The common 
site of occurrence is the posterior and anterior uveal tract. Primary or secondary 
involvement of the eye can occur. Primary disease is the result of direct inoculation 
by contaminated fingers, dust or droplet nuclei from sputum and is rare. This results 
in conjunctivitis, corneal ulcerations or abscess formation. The causative organism 
could be M. tuberculosis or M. fortuitum. In secondary TB infection of the eye the 
organism reaches the eye via the blood and this may be the only manifestation of the 
disease (Waldman, 1982).  
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2.8  DIFFERENTIAL DIAGNOSIS 
A differential diagnosis for oral TB should include malignancy, traumatic and 
aphthous ulcers, syphilis, sarcoidosis and deep mycotic infections (Von Arx and 
Husain, 2001; Eng et al. 1996; Dimitrakopoulos et al. 1991; Hashimoto and Tanioka, 
1989; Rauch and Friedman, 1978; Brennan and Vrabec, 1970). Differential diagnosis 
for TB of the jaw is non-specific inflammation, actinomycosis, neoplastic lesions or 
osteogenic sarcoma (Mavropoulou and Yannoulopoulos, 1986) and lymphoma or 
secondary metastasis in the neck (Al-Serhani, 2001).  
2.9 DIAGNOSIS 
Table 1: Patient history prompting suspicion of active TB  
 
1 Productive cough (>3 weeks) – pulmonary TB 
2 Other symptoms (fever, chills, night sweats, fatigue, chest pain, loss of appetite 
and weight, weakness, coughing up blood) 
3 Extra-pulmonary TB (occurs in 15% of cases) 
4 Patients with TB and HIV infection – 40-75% have extra-pulmonary TB and 
pulmonary TB 
5  History of TB exposure and/or previous TB infection (active TB) 
Source: Davidsons (2002): 528 
A diagnosis of infection with M. tuberculosis relies on (i) development of a positive 
delayed hypersensitivity (tuberculin) skin reaction to purified protein derivative 
(PPD), a mycobacterial antigen isolated from bacterial cultures and (ii) 
demonstration of acid-fast mycobacteria in clinical specimens. Information obtained 
while collecting a patient’s medical history can provide evidence of suspicion of TB 
(Table 1) (Davidsons, 2002). 
The tuberculin skin test measures the body's immune response to an injection of 
tuberculin   PPD. The Mantoux test injects a known amount of PPD between the 
layers of skin (intra-dermally). The reaction to the test at the site of injection is 
measured 48-72 hours later. A positive test indicates infection with TB, but not 
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necessarily TB disease. A negative tuberculin skin test does not exclude TB. The 
tuberculin skin test is a low sensitivity or specificity test which is useful only in 
primary or deep-seated infections.  
 
If the chest X-ray is typical of TB and the skin test is negative, TB can be diagnosed. 
Conditions which may suppress the tuberculin skin test and give a false negative 
result include: HIV infection, malnutrition, severe viral infections (eg. measles, 
chicken pox), cancer, immunosuppressive drugs (eg. steroids) and severe 
disseminated TB (Randy et al. 1993).  
 
Direct microscopy of samples (Ziehl-Neelsen or auramine staining) and culture can 
confirm mycobacterial infection. The BACTEC system (automated detection system 
for mycobacteria) is used to obtain drug susceptibility profiles. Molecular methods 
which allow the detection of rifampicin resistance (a marker for MDR) is used when 
MDR-TB is suspected. Diagnosis of TB using specimens includes the following: For 
respiratory – Sputum, gastric washing, bronchoalveolar lavage and transbronchial 
biopsy and for non-respiratory – fluid examination and tissue biopsy. Diagnosis of 
TB using diagnostic tests include circumstantial (ESR, C-reactive protein, anaemia), 
tuberculin skin test, stains, nucleic acid amplification, culture and response to 
empirical antituberculous drugs. Tuberculin skin testing uses the Heaf or Mantoux 
technique (Davidsons, 2002). 
Examination of oral tissues using acid-fast staining methods may produce negative 
results due to a paucity of bacilli in oral lesions. This method does not differentiate 
between the various types of mycobacteria. Biopsy of the lymph nodes using fine 
needle aspiration and the acid-fast staining and culture methods can achieve a 
definitive diagnosis without open biopsy. Pulmonary TB even in those patients 
without systemic signs and symptoms is ruled out by chest radiographs. In cases of 
negative sputum smears, pulmonary TB is confirmed using acid-fast smear and 
culture of laryngeal swabs. PPD tests should be done routinely, although the BCG 
vaccination may produce a positive reaction. Immuno-compromised patients may 
produce false-negative results (Bhatt and Jayakrishnan, 2001).  
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2.10 RISK FACTORS  
The re-emergence of M. tuberculosis as a significant public health problem in South 
Africa appears to be the result of a combination of changing host susceptibility 
factors and declining social conditions. The most frequent risk factor is infection 
with HIV (Small et al. 1991; Barnes et al. 1991; Theuer et al. 1990; Reider et al. 
1989; Selwyn et al. 1989). The suppressive effect of HIV infection on cell-mediated 
immunity increases host susceptibility to a variety of microbial pathogens that are 
normally controlled by these defence mechanisms.  
Table 2: Risk factors associated with TB  
1 Known or suspected HIV infection 
2 Persons with close contacts with infectious persons – exposure to a pulmonary 
TB case, especially a sputum smear-positive case 
3 Persons with medical conditions that increase the risk of contracting HIV 
4 Intravenous drug abusers 
5 Persons from low socio-economic groups 
6 Malnutrition: Marasmus Kwashiorkor in children 
Chronic alcohol abuse which is associated with malnutrition 
Poor nutrition in any individual 
7 Medications: Long term cortisone therapy 
Chemotherapy for malignancies or transplants 
8 Stress: Mental or physical stress can cause suppression of the immune system 
9 Prisoners 
10 Industrial silica dust exposure (eg. In underground miners) 
Source: Davidsons (2002): 529 
 
2.11  TREATMENT, CONTROL AND PREVENTION   
Prior to the advent of antimicrobial chemotherapy, approximately 50% of people 
with active TB died within two years after the onset of symptoms (Styblo, 1980). 
Regimens of multiple antibiotics are currently used to treat patients with active TB to 
ensure tissue penetration and minimise emergence of resistant organisms.  
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General guidelines for appropriate chemotherapy include the necessity for long-term 
treatment intervals, initiation of treatment if sputum smear is positive for acid-fast 
bacilli and patient compliance (a major factor in determining chemotherapy success) 
(Davidsons, 2002). 
The key factor in the principles of treatment to stop the spread of TB in a community 
is to start treating patients who are coughing up living bacilli as soon as possible. It is 
crucial that correct drugs are given for the correct period of time for treatment to be 
effective. It must be established whether the patient is a new patient (has never been 
treated for TB before) or a retreatment patient (treated for more than four weeks at 
any time in the past). Treatment with a combination of drugs is the best. Patients 
must take the treatment for five days a week. No trials of therapy should be given as 
this is one of the reasons for an increase in drug resistance (DOH, 2000).  
The three main properties of the essential anti-TB drugs are bactericidal, sterilizing 
and the ability to prevent resistance. Isoniazid and Rifampicin are the most powerful 
bactericidal drugs, active against all populations of TB bacilli. Pyrazinamide and 
streptomycin are bactericidal against certain populations of TB bacilli. Pyrazinamide 
is active in an acid environment against TB bacilli inside macrophages. Streptomycin 
is active against rapidly multiplying extracellular bacilli and Ethambutol is 
bacteriostatic (DOH, 2000). If the patient is an irregular attendee in the intensive 
phase of treatment (more than 10 missed doses), the standardized re-treatment 
regimen must be started. If more than two months in the continuation phase of 
treatment is missed, the continuation phase must be completed if the sputum smear is 
negative and retreatment must begin if the sputum is smear positive. Retreatment 
patients should be hospitalized for the initial two months as they are more likely to 
develop MDR (DOH, 2000).  
The DOTS strategy, which is the only globally recognised strategy for effective TB 
control, ensures that infectious TB patients are identified and cured using 
standardized drug combinations. Patients are observed by treatment supporters as 
they swallow their drugs daily. The treatment supporter can be a responsible member 
of the community, employers or colleagues. The person should know the signs and 
symptoms of TB, side effects of TB drugs and the importance of regular intake of TB 
medication.  
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The DOTS strategy is the most effective strategy available for controlling TB. It was 
adopted by the South African National Department of Health after it was realized that 
their TB control efforts had been ineffective. The five key elements of the DOTS 
strategy are outlined in Table 3 (DOH, 2000). 
 
Table 3: DOTS Strategy 
 
 
1 Government commitment to sustained TB control activities. 
 
2 Sputum smear microscopy to detect the infectious cases among those people 
attending health care facilities with symptoms of TB, most importantly cough of 
three week’s duration or more. 
3 Standardized short-course anti- TB treatment for at least all confirmed sputum 
smear positive pulmonary TB cases, with direct observation of treatment for at 
least the initial two months. 
4 A regular, uninterrupted supply of all essential anti-TB drugs. 
5 A standardized recording and reporting system which allows assessment of 
treatment results and overall programme performance. 
Source: DOH (2000): 9 
 
The priority of DOTS is to cure infectious patients and its core elements are outlined 
in Table 4 (DOH, 2000). 
 
Table 4: Core Elements of DOTS 
1 Sustained TB control activities 
2 Sputum smear microscopy to detect the infectious cases among those people 
attending health care facilities with symptoms of TB, most importantly cough 
of three week’s duration. 
3 Standardized short-course anti-TB treatment with direct observation. 
4 An uninterrupted supply of TB drugs. 
5 A standardized recording and reporting system which allows assessment of 
treatment results. 
Source: DOH (2000): 5 
 
 
The DOTS strategy is effective in treating TB but may be insufficient in treating 
MDR-TB therefore the DOTS-plus programme was implemented for the treatment of 
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MDR-TB patients. DOTS-plus involves the use of second-line anti-tuberculosis 
drugs which are more toxic and expensive and less effective than first-line drugs.  
The regimen includes two or more drugs to which the isolate is susceptible, including 
one drug given parenterally for more than six months. The total duration of treatment 
is 18-24 months and treatment is directly observed. Optimal use of the DOTS-plus 
programme can lower mortality caused by TB and MDR-TB (Sterling et al. 2003).  
In South Africa the standardised approach to DOTS-plus comprises of treatment at 
dedicated MDR-TB referral facilities where patients are admitted for four months of 
therapy or until sputum conversion, specialised teams overseeing all aspects of 
MDR-TB management, patients being regularly monitored and documented (patients 
registered on the DOTS-plus Electronic Register at the MDR-TR referral centres) 
and ambulatory treatment after discharge provided DOT is ensured and patient 
follows up for five years after treatment completion at six monthly intervals (Weyer, 
2005).  
BCG, an attenuated strain of Mycobacterium bovis, has been used for more than 80 
years to protect humans against TB and is up to 80% protective in 10-15 year olds, 
but less so in adults. It is recommended for those that do not respond to tuberculin. 
Those that respond to tuberculin skin tests should be referred for clinical and 
radiological examinations.  
TB is the most significant cause of mortality in people living with HIV in developing 
countries therefore good treatment outcomes is critical to decrease HIV-related 
morbidity and mortality. A combination of cure and completion rates results in 
treatment success. High default and loss to follow up rates could be improved 
through strengthened DOT and community adherence programmes. Community 
workers assist by confirming addresses, educating patients about the importance of 
good adherence, encouraging patients to go to health facilities for sputum smear 
examinations at the end of the intensive and continuation phases and tracing 
defaulters. The critical challenges to effective TB control are highlighted in Table 5 
(Grimwood et al. 2006).  
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Table 5: Critical challenges to effective TB control in South Africa 
1 Poor financial and human resources support to the TB programme. 
2 Poor support of the TB programme especially at provincial level 
3 Poor management of patients which leads to patients defaulting from 
treatment  
4 High mobility of patients especially in the urban areas and poor referral 
systems 
5 Late detection of patients 
6 Inaccessible and of questionable quality laboratory services  
7 Lack of knowledge of TB and the importance of completing treatment 
8 Poverty 
9 Co-infection of patients with TB and HIV 
Source: Adapted from Grimwood et al. (2006): 82 
2.12  CHEMOTHERAPY 
Chemoprophylaxis is administered to prevent infection progressing to clinical 
disease and is recommended for under 16 year olds with strongly positive Heaf tests, 
under 2 year olds in close contact with smear-positive pulmonary disease, those in 
whom recent tuberculin conversion has been confirmed, and babies of mothers with 
pulmonary TB. It should also be considered for HIV-infected close contacts of a 
patient with smear-positive disease. Rifampicin and isoniazid for 3 months, 
rifampicin and pyrazinamide for 2 months, or isoniazid for 6 months are all effective.  
Short-course therapy consists of 2 months with 4 drugs (rifampicin, isoniazid, 
pyrazinamide and either ethambutol or streptomycin) followed by 4 months of 
rifampicin and isoniazid is now recommended for all patients with new onset, 
uncomplicated pulmonary or extra-pulmonary TB. Ethambutol or streptomycin can 
be omitted in patients in whom isoniazid resistance is unlikely. Longer treatments (9-
12 months) are considered for patients with meningeal disease, HIV co-infection or 
drug intolerance. With adherence to drug therapy and where the strain is fully 
sensitive, relapse would be rare.  
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Four drugs must be used on patients with a history of past treatment. MDR-TB 
treatment is complex and depends on the sensitivity of the isolate.  
The patient is admitted to a negative-pressure isolation room until non-infectious and 
five or more drugs are used for treatment. Most patients can be treated at home. 
Patients can be assumed to be non-infectious after 2 weeks of quadruple therapy and 
where drug resistance is not expected. DOTS are recommended for non-compliant 
patients, MDR patients and in patients with language difficulties. DOTS therapy is 
recommended globally by the WHO for all patients with TB (Davidsons, 2002). 
MDR strains make TB more costly and difficult to treat. There is therefore a need for 
newer and more effective drugs that can achieve multiple goals in improving TB 
control (Tovaru et al. 2008). 
Short-course therapy using 4 drugs is curative in the absence of major complications. 
Patients can die from infections due to miliary disease or bronchopneumonia. 
Mortality is increased in HIV-associated TB as a result of superimposed bacterial 
infection. (Davidsons, 2002).                                                                         
2.13  ORAL HEALTH CONSIDERATIONS 
The risk of TB transmission from patients to oral health care workers is considered to 
be minimal (Cleveland et al. 1995). However, M. tuberculosis is uniquely hazardous 
to oral health care workers because of its airborne route of transmission, lack of 
effective vaccination, the long and tedious treatment regimen, presence of resistant 
strains and the long-term sequelae of the infection. Historically, tuberculosis has been 
regarded as an occupational hazard for oral health care workers; presently persons 
who work with high-risk patients or in high prevalence communities are still 
considered at risk for new infection.  
Standard precautions provide the fabric for strategies to prevent or reduce the risk of 
exposure to blood borne pathogens and other potentially infectious material. 
However, standard precautions are inadequate to prevent the spread of organisms 
through droplet nuclei 1-5 microns in diameter and additional measures are necessary 
to prevent the spread of M. tuberculosis.  
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The magnitude of risk varies by setting, occupational group, and prevalence of TB in 
the community, patient population served in the setting, procedures performed and 
effectiveness of TB infection-control measures. Every setting in which services are 
provided to persons who have suspected or confirmed TB disease should have a TB 
infection-control plan. The probability of a person exposed to M. tuberculosis 
becoming infected depends on the concentration of infectious droplet nuclei in the air 
and the duration of exposure to a person with infectious TB disease (CDC, 2005). 
Environmental factors such as exposure in confined spaces, inadequate ventilation 
and recirculation of air containing infectious droplet nuclei further increase the 
likelihood of transmission (American Thoracic Society, CDC, 2000). Cases with 
positive smears are highly infectious. Prior to the AIDS epidemic it was accepted that 
pulmonary cavity formation was necessary for contagiousness. However, patients 
with AIDS and pulmonary TB may be highly contagious in the absence of cavitations 
and normal chest radiographs. This results in delayed diagnosis and a greater risk of 
nosocomial transmission.  
There is a paucity of data linking dental instrumentation to the generation of droplet 
nuclei containing M.  tuberculosis (Duell and Madden, 1970; Belting et al. 1964). 
Similarly, the reported incidence of tuberculin skin test conversion among oral health 
care workers is low (Porteous and Brown, 1999; Mikitka et al. 1995; CDC, 1993). It 
can however be anticipated that oral health care workers and patients with infectious 
TB disease will generate droplet nuclei by coughing, sneezing, laughing and talking; 
therapeutic intervention could stimulate coughing and promote the generation of 
infectious particles. Since patients and oral health care workers share the same air 
space, the potential for the transmission of M. tuberculosis cannot be discounted 
(Naidoo and Mohammed, 2002). Infection control procedures at dental practices 
should include knowledge of the signs and symptoms of active TB, an updated 
medical history related to respiratory illness and referral of suspicious patients for 
medical evaluation.  
Hand-washing must be done prior to and following patient contact, instruments must 
be sterilised and contaminated working surfaces must be disinfected with phenol and 
glutaraldehyde. Well-constructed, soft, pleated, high-filtration face masks must be 
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worn when aerosols are produced during dental treatment. Masks must be kept dry to 
avoid microbes passing through.  
Aerosols can be reduced by avoiding the use of water spray from the triplex syringe, 
use of rubber dams and high volume suctions. The probable transmission of MDR TB 
disease from patients to two oral health care workers has been documented in the 
United States, and there is evidence of TB disease transmission from an oral surgeon 
to 15 patients following extractions (Cleveland et al. 1995; Smith et al. 1982).  
The 2005 CDC guidelines for preventing the transmission of M. tuberculosis in 
healthcare facilities explicitly identify oral healthcare settings as outpatient settings in 
which patients with suspected or confirmed infectious TB disease are expected to be 
encountered (CDC, 2005). This inclusion is based on the assumption that patients 
with infectious TB disease may present in the dental setting for urgent or routine 
dental care and oral health care workers might share air space with persons with 
infectious TB disease or might come in contact with clinical specimens that contain 
M. tuberculosis.  
Therefore, every oral healthcare facility should have a TB infection-control plan that 
is part of its written infection control/exposure control protocol. The TB infection-
control component of an overall infection control/exposure control programme should 
be appropriate for the level of risk in the specific health care setting and should be 
based on a three-level hierarchy of administrative, environmental and respiratory-
protection controls (CDC, 2005; Kohn et al. 2004; CDC, 2003; Cleveland et al. 
1994).  
The first and most important level in the TB infection-control program is the 
implementation of administrative controls which includes: (i) conducting a TB risk 
assessment for the oral health care setting, (ii) developing, implementing, and 
enforcing a written TB infection-control plan to ensure prompt detection, airborne 
infection isolation and treatment of persons with suspected or confirmed TB disease, 
(iii) implementing an ongoing training and education programme, and (iv) screening 
and evaluating oral health care workers who are at risk for TB disease or who might 
be exposed to M. tuberculosis.  
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These administrative controls are intended to reduce the risk of exposure to persons, 
who might have infectious TB disease, and they are essential prerequisites for the 
effectiveness of environmental controls and respiratory-protection controls in all 
settings where patients with suspected or confirmed TB disease are expected to be 
encountered (CDC, 2005).  
Although the overall risk of oral health care workers for exposure to a patient is 
probably low, every oral healthcare setting should conduct initial and ongoing 
(annual) evaluations of TB risk for the setting and determine the demographics of the 
patient population served in that setting (CDC, 2005). This will determine the types of 
administrative, environmental, and respiratory-protection controls that are needed for 
the particular setting. Consultation with the local or state health department must be 
done.  
Contact with patients with undiagnosed or unsuspected infectious TB disease is the 
primary risk of exposure to M. tuberculosis in the oral healthcare setting. A high 
index of suspicion and rapid implementation of precautions are essential to prevent 
and interrupt the transmission of M. tuberculosis. Specific precautions will vary 
depending on the setting, i.e. prevalence of TB in the community, patient population 
served and the type of services provided in a particular setting. The minimum 
requirements in a community-based oral healthcare setting is the implementation and 
enforcement of a TB infection-control protocol that provides (i) prompt identification 
of patients with suspected or confirmed infectious TB disease, (ii) separation of 
patients with suspected and confirmed TB disease from other oral health care workers 
and patients, and (iii) referral of patients with suspected and confirmed TB disease for 
a medical evaluation and/or required oral healthcare procedures to a facility with 
appropriate environmental controls and respiratory protection controls (CDC, 2005).  
An essential part of administrative controls in a TB infection-control programme is 
the education and training of oral health care workers which include all paid and 
unpaid persons working in the oral healthcare setting who have the potential for 
exposure to M. tuberculosis through air space shared with persons with suspected or 
confirmed infectious TB disease (CDC, 2005). Risk classification for the setting will 
determine the need for and frequency of TB screening for oral health care workers. 
Oral healthcare facilities are considered medium risk settings.  
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All oral health care workers should receive baseline TB screening at the time of hire. 
Follow-up TB screening should be performed annually. Oral health care workers with 
positive results should be evaluated promptly for TB disease. Radiographs are also 
important as part of the evaluation. Preventive therapy should be offered to all 
personnel with baseline-positive results. Personnel with TB disease should be 
excluded from the workplace until they are receiving adequate therapy, their cough 
has resolved and their sputum smears are negative (CDC, 2005).  
The concept of universal precautions is the key element of infection control in 
dentistry since medical history and examination cannot reliably identify all patients or 
carriers of infections. All patients must therefore be regarded as potentially infectious. 
Deferral of non-emergency care may be indicated when patients present for dental 
treatment with diseases such as TB and they should then be treated when they are 
non-contagious.  
Patients requiring urgent dental treatment should be referred to a facility with TB 
engineering controls and a respiratory protection programme. Patients should wear a 
surgical mask or be instructed to cover mouth and nose when coughing or sneezing 
when they are not being evaluated. In order to minimise the spread of respiratory or 
other diseases in dentistry emphasis should be placed on vaccination, use of 
particulate respirators and adequate ventilation. The BCG vaccine is an effective 
measure that can help control the spread of TB and should be administered to oral 
health care workers in geographic regions or clinical settings where there is a high 
prevalence of TB.  
In addition the surgery should have good ventilation; aerosols should be controlled by 
high volume externally vented aspirators and wearing of particulate respirators. 
Facemasks routinely used by oral health care workers may not always provide an 
effective means of preventing infection. Oral health care workers need to be alert to 
signs and symptoms of TB and refer such individuals for appropriate medical health 
care (World Dental Federation (FDI), 2003). A TB screening programme should be 
established for the protection of both workers and patients. The prevalence of TB in 
the community or patient population indicates a potential risk for occupational 
exposure to TB.  
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Tuberculin skin testing data should be evaluated regularly to enable the dental 
personnel to evaluate the effectiveness of current infection control practices 
(Cleveland et al. 1995).   
The resurgence of TB as a public health problem, the explosive outbreaks of TB 
among AIDS patients, reports of transmission to staff and the emergence of drug 
resistant strains have refocused attention on the risk to oral health care workers and  
has rekindled interest in this disease among oral health care workers. However, much 
research has focused on pulmonary and extra-pulmonary TB involving the abdomen 
and spine and there is a paucity of literature on the head and neck region. Extra-
pulmonary presentations form a significant proportion of new cases concomitant with 
HIV epidemic. The increase in numbers of HIV seropositive individuals and the late 
diagnosis of TB in these patients because of atypical signs and symptoms, suggest that 
oral health care workers may be unknowingly treating infected patients who pose a 
risk. The generation of aerosols in modern dentistry is a recognised risk for 
transmission of infection which is droplet spread. Systemic symptoms may be absent 
and oral lesions may be the first manifestation of the disease. Therefore oral health 
care workers need to be aware of TB in the head and neck region and its varied 
manifestations. 
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CHAPTER 3: AIMS AND OBJECTIVES  
  
 
3.1  AIM 
To determine the extent to which tuberculosis presents in the head and neck region. 
 
3.2  OBJECTIVES 
¾ To retrospectively ascertain the presentation of head and neck tuberculosis. 
¾ To describe the management and outcomes of head and neck tuberculosis. 
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CHAPTER 4: METHODOLOGY  
 
This chapter presents the aims and objectives of the study, the study design, sampling, 
matching and inclusion criteria. In addition, the survey method, development and 
piloting of the data capture sheet, data entry and method of analysis are described. 
 
4.1  INTRODUCTION 
 
The resurgence of TB as a public health problem, especially in South Africa, has 
rekindled interest in this disease among oral health care workers. The TB epidemic in 
South Africa is likely to be exacerbated over the next few years due to the high 
prevalence of HIV/AIDS. Much research has focused on pulmonary and extra-
pulmonary TB involving the abdomen and spine and there is a paucity of literature on 
the head and neck region. Extra-pulmonary presentations form a major proportion of 
new cases concomitant with the HIV epidemic. Systemic symptoms may be absent 
and oral lesions may be the first manifestation of the disease. Therefore oral health 
care workers need to be aware of TB in the head and neck region and its varied 
manifestations. 
 
This study was attempted due to the fact that there is no epidemiological data 
available on head and neck TB in South Africa. With this background, and the paucity 
of literature related to dentistry, the aim of this study was to determine the extent to 
which tuberculosis presented in the head and neck region in Kwa-Zulu Natal. 
 
4.2 LIMITATIONS OF STUDY 
 
The study could not be conducted as a prevalence study as originally planned, but 
instead reports on the descriptive data of a convenience sample of 104 patients 
presenting with head and neck tuberculosis. 
 
The initial plan for data collection was to be over a period of 10 years and information 
was to be obtained from the various hospitals in the Durban area. The hospitals 
approached were King Edward, Addington, Albert Luthuli, King George, RK Khan 
and Prince Mysheni Unfortunately this was not possible. King Edward, RK Khan and 
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Prince Mysheni refused permission saying that they did not see patients with head and 
neck TB although they had an Ear, nose and throat (ENT) Department. Addington 
refused permission on the grounds that there were too many researchers at their 
hospital. The reason given by Albert Luthuli was that all their records were on 
computer and that they could not give access to their passwords in order to access 
records. Permission to access data was only granted by King George Hospital. It was 
not an easy task to identify patients with head and neck TB from the patient register 
and this would have entailed going through many thousands of records to find cases 
and this would have been like “looking for a needle in the haystack”. An attempt was 
then made to identify patients with positive head and neck TB through a provincial 
lab search at Albert Luthuli Hospital. This too proved futile as the researcher was not 
allowed to access the data herself and the searches were done by staff. They could not 
identify any patients from their system with positive head and neck TB.   
 
Due to the difficulty experienced in obtaining data from hospital records it was then 
decided to source patients from private practices. Contact was made with Physicians, 
Surgeons and the ENT society through their chairperson. The study protocol and 
ethical approval was presented to them and they were then prepared to assist with the 
research. Due to the enormity of the task and subsequent advice from one of the ENT 
specialists, contact was then made with Lancet Laboratory to assist in identifying 
patients with positive TB in the head and neck region. Records from January 2008 to 
present could only be accessed. Hence, the present study reports on cases diagnosed 
over a period of fourteen months. Once the patients were identified, the various 
practices were contacted for permission to access patient records.  
 
4.3  STUDY DESIGN 
 
This present study was a descriptive, retrospective, record based study on a cohort of 
TB patients that presented with head and neck TB. Information from patient records 
was extracted and recorded in a structured data capture sheet (Appendix 1). Data from 
patients attending the private ENT specialists, physicians and surgeons was recorded. 
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It was anticipated that the descriptive study would summarise routine data and would 
quantify the extent of a health problem or the burden of disease in a population. This 
descriptive study was limited to the prevalence of the occurrence of disease in a 
population. Descriptive studies provide information to health care planners that will 
help them develop appropriate services, allocate resources, decide on priorities, and 
target certain populations. A retrospective study would shorten the time needed to 
conduct a cohort study as it makes use of historically or previously compiled data.  
 
4.4  STUDY SITES 
 
Private practices of four ENT specialists, eight Physicians and seven Surgeons. 
 
4.5  SELECTION OF STUDY POPULATION 
 
The study population was a convenience sample including all patients attending the 
various practices. The study sample included all patients diagnosed with head and 
neck TB at these practices. 
 
4.6  STUDY POPULATION AND SAMPLING 
 
A search was conducted at the lab on 36 practices in the Durban region in order to 
identify the patients with TB of the head and neck region. Of these searches only 26 
of the practices had patients with positive head and neck TB. Of these 26 practices 
only 19 of them allowed me access to patient records. The study sample included all 
patients diagnosed with head and neck TB at these practices.  
 
4.7  INCLUSION CRITERIA 
 
Patients diagnosed with TB and with head and neck TB. 
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4.8  INSTRUMENT 
 
A structured data capture sheet was the method chosen for collecting the data 
(Appendix 1). The data capture sheet was designed to ensure that it suited the aims 
and objectives of the study, was clear, simple and unambiguous, minimized potential 
errors from the researcher and coder and enabled efficient, meaningful analysis of the 
acquired data. 
The structured data capture sheet was used to determine the:- 
¾ Age and gender of the patient 
¾ Presenting symptoms 
¾ Type of examination and investigations done 
¾ Type of head and neck TB 
¾ Treatment and management of head and neck lesions 
¾ Other sites (apart from head and neck) presenting with TB 
¾ Response to treatment 
 
4.8.1  Development of the data capture sheet 
 
Planning of the data capture sheet began in February 2008. It was developed from 
information obtained from the review of literature on head and neck TB. For the 
purpose of this study, the data gathered was divided into six sections: (i) demographic 
– age and gender of the patient; (ii) HIV/AIDS status; (iii) presenting signs and 
symptoms; (iv) examinations and investigations; (v) head and neck sites and other 
sites involved; (vi) treatment provided and (vii) the outcomes.  
 
4.8.2  Piloting the data capture sheet 
A pilot study was conducted to test the data capture sheet in terms of practicability 
and relevance. The pilot study was carried out to: 
(i) test the suitability of the method of collecting the data 
(ii) test how long it would take to record information from patient cards 
(iii) check the adequacy of the data capture sheet 
(iv) check that all the parameter measurements were clear and unambiguous 
(v) ensure that no major item had been omitted and 
(vi) remove any items that did not yield usable data. 
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4.8.3  Preparation of the final draft 
 
After the pilot study, irrelevant and problematic items was identified and deleted or 
reformulated. A final draft of the data capture sheet was then printed and used for the 
final study.  
 
4.9  DATA COLLECTION METHODS 
 
Once the patients with positive TB in the head and neck region were identified at the 
lab, their cards were obtained from the various practices and the information was 
recorded in the data capture sheets. The following information was recorded on the 
data capture sheets: patient number, age, gender, HIV/AIDS status, presenting signs 
and symptoms, types of examinations and investigations, head and neck sites and 
other sites involved, treatment provided and the outcomes.  
 
4.10  VALIDITY AND RELIABILITY 
 
The researcher was the only investigator involved in the gathering and interpretation 
of the data thereby assuring the standardized recording of all the information 
presented. To ensure validation of the data capture sheets, the instrument was 
subjected to a test-retest procedure (by repeatedly administering the scales to the same 
sample within a short period). 
  
4.11  DATA ANALYSIS 
 
Following the literature review, the study selected the relevant statistical tests required 
and the data was processed after the information was loaded onto the SPSS15 system 
and analysed by the researcher. Interpretation of all the statistical data was done by 
the researcher with assistance from a statistician. 
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4.12  PROCEDURES 
 
4.12.1 Establishing contacts 
 
Access to the participating hospitals was initially made by a telephone call followed 
by a visit to meet the staff working at the ENT clinics at these hospitals. A letter 
(Appendix 2) with the ethical approval and protocol was then sent to hospital 
managers. A letter of approval was required from the various hospitals that had to be 
sent to Health Research Ethics Committee at the Department of Health for final 
approval to access data at these hospitals. Permission was granted by only one of the 
six hospitals identified for this research project. The letters (Appendix 2, Appendix 3 
and Appendix 4) with the protocol was then sent to Health Research Ethics 
Committee at the Department of Health. A final approval letter (Appendix 5) was 
received from Health Research. This letter was then forwarded to the hospital that had 
granted permission to access records. An introduction of the researcher, the basic aims 
and objectives of the study, what participating in the study would involve and how 
long the examination would take, were explained. It was emphasized that strict 
confidentiality would be maintained at all times and that the results of the study would 
be presented in a manner that ensured anonymity.  
 
Once signed, approval had been obtained from the Hospital managers and 
arrangements were made to access patient clinical records at a time convenient to the 
participating hospital.  
 
When obtaining data from the hospital proved futile, contact was then established 
with the private ENTs, Physicians and Surgeons to access data at their private 
practices. The data capture sheet (Appendix 1) together with the letters (Appendix 2 
and 3) were sent to the private practitioners. When identifying patient records with 
positive head and neck TB proved difficult at the private practices, contact with 
Lancet Laboratory was established to identify these patients.  
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4.12.2 Ethical considerations 
 
The study protocol was submitted to the Senate Research Ethics Committee of the 
University of the Western Cape for ethical approval. Approval was granted through a 
letter (Appendix 3).  Permission was sought from the relevant persons to access 
records. It was emphasized that strict confidentiality would be maintained at all times.  
 
4.13  CONCLUSION  
 
This chapter described the selection of the study population which included a 
laboratory search to identify the patients. Establishing contacts and accessing 
information was not an easy task - practitioners were very uncooperative and refused 
permission. The instrument developed to collect the data was a focused, structured 
data capture sheet in six parts and the piloting of it is described in this chapter. 
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CHAPTER 5: RESULTS 
 
This chapter presents the findings of the study. It describes the demography of the 
sample of patients that presented with head and neck TB, the association with HIV, 
the presenting complaints, examinations and investigations that were performed, the 
head and neck sites that were involved, the treatment that was carried out and the 
outcomes of patient management. 
 
5.1  DEMOGRAPHY 
 
The study included one hundred and four cases of TB of the head and neck region 
from nineteen private practices in the Durban region. The regions included the city 
centre, north, north central, south and south central. The twelve practices in the city 
centre and surrounding area made up the majority of the patients (69%), four practices 
in the south central region made up 4% of the patients, the north central region where 
five practices were visited made up 24% of the patients and the north region where 
one practice was visited made up 3% of the patients. Forty one patients (39.4%) were 
male and sixty three (60.6%) were female. The age ranged from one year to sixty one 
years. TB of the head and neck region presented most commonly in the thirty-one to 
forty year age group (Table 6), which comprised of 43% of the total number of patient 
records examined.  
 
Table 6:  Age Distribution of TB Head and Neck 
 
Age Range Percentage of  Patients 
0 – 20 7% 
21 – 30 23% 
31 – 40 43% 
41 – 50 20% 
50 and above 7% 
Total 100% 
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Seventy seven (74%) of the patients with head and neck TB were of African (Black 
origin) and twenty seven (26%) were of Asian origin. Patient records indicated a 
greater preponderance to females presenting with head and neck TB (sixty two (42%) 
of females in comparison to forty two (32%) males). Thirty five (33.7%), which made 
up a third of the patients, was confirmed with HIV. Lymph nodes which were found 
in ninety three (89.4%) of the patients was the most common site of head and neck 
TB. 
 
5.2  PRESENTING COMPLAINTS 
 
Thirteen patients (12.5%) presented with fever, two (1.9%) with weight loss, 
seventeen (16.3%) with cough, five (4.8%) with hoarseness, two (1.9%) with 
odynophagia, ten (9.6%) with dysphagia, and eight (7.7%) with otalgia. The 
presenting complaints of forty seven (45%) of the patients were not recorded. Other 
signs and symptoms included a neck abscess, neck mass, headaches and pain. The 
details of the presenting complaints at the individual sites are described below.  
 
5.3  EXAMINATIONS AND INVESTIGATIONS 
 
Investigations included one (1%) needle aspiration, thirty five (33.7%) chest x-rays, 
fifteen (14.4%) sputum culture, five (4.8%) PPD, twelve (11.5%) pus culture and 
sensitivity. One hundred and two (98.1%) excision biopsies and one hundred and 
three (99%) histological examinations were done. Other investigations included full 
blood surveys, scans, ultrasounds, bronchoscopy and laryngoscopy.   
 
5.4 HEAD AND NECK SITES OF TUBERCULOSIS 
 
TB of the head and neck presented most commonly in the lymph nodes of the head 
and neck region (Table 7). The second most common site was the tonsil. Other sites 
included the ethmoid sinus and the mastoid process. No patients were identified with 
TB of the cervical spine, tongue, hard palate, soft palate, mandible, tempero-
mandibular joint, maxilla, buccal mucosa, gingiva, floor of the mouth and lips.  
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Table 7:  Percentage distribution of the head and neck sites 
 
Head and neck site Number  Percentage 
Head and neck lymph nodes 93 89.4% 
Tonsil 5 4.8% 
Larynx 2 1.9% 
Ear 2 1.9% 
Parotid Gland 1 1% 
Nose 1 1% 
Total 104 100% 
 
 
The presentation of lymph nodes was slightly higher (Figure 1) on the right side of the 
head and neck region, twenty three (25%), as compared to twenty one (23%) on the 
left hand side. The specific side of sixteen (16%) of the lymph nodes were not 
recorded (Figure 1). This is reflected as unspecified side (16%).  
 
Figure 1:  Percentage distribution of lymph nodes on the left and right side of 
neck and unspecified side  
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5.5  OTHER SITES 
 
Additional sites of TB that were found were twelve (11.5%) with TB of the lung, five 
(4.8%) with TB of the abdomen and one (1%) in the liver.  
 
5.6  TREATMENT 
 
Just over two thirds (62.5%) of the patients treatment for chemotherapy, isoniazid, 
rifampicin, pyrazinamide, ethambutol, ARTs and radiotherapy was not recorded. Of 
the patients that were recorded one, (1%) had chemotherapy, eleven (10.6%) were put 
on Isoniazid therapy, twenty nine (27.9%) were on Rifampicin, thirty one (29.8%) on 
Pyrazinamide, ten (9.6%) on Ethambutol, seventeen (16.3%) were on ARTs and one 
hundred and three (99%) had surgery performed.  
 
5.7  OUTCOMES 
 
Of the sample of 104 patients, five (4.8%) had survived and were in remission, four 
(3.8%) were lost to follow up, eighty (76.9%) were transferred to their referring 
doctors, three (2.9%) were not evaluated and 12 (11.5%) were still on treatment.  
 
5.8  COEXISTING DISEASE 
 
Just over ten per cent (11.5%) had co-existing pulmonary TB, five (4.8%) had TB of 
the abdomen and 1 (1%) had TB of the liver. A third (33.7%) was HIV positive – the 
majority of the HIV positive patients (97%) presented with TB of the lymph nodes. In 
addition to TB of the head and neck, nearly a third (29%) of the HIV positive patients 
had associated lung TB, three (9%) had associated TB of the abdomen and one (3%) 
had TB of the liver.   
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5.9  RESULTS FOR INDIVIDUAL SITES 
 
5.9.1  Tuberculosis of the lymph nodes  
 
Majority of the patients which was 93 (89.4%) suffered from tubercular 
lymphadenitis. Six patients (7%) presented with discrete cervical node swelling, six 
patients (7%) presented with matting and four patients (5%) with ulceration and 
discharge. The most commonly involved lymph node group was the cervical left 
(15% - Figure 1). One of the patients that presented with a neck abscess was a one 
year female child who was confirmed with HIV. Tests included sputum, excision 
biopsy and histology.  
 
5.9.2  Tuberculosis of the larynx 
 
The two patients with TB of the larynx consisted of a sixteen year old female and a 
thirty two year old male patient. The presenting signs and symptoms were cough, 
hoarseness, dysphagia and discomfort in the throat. Investigations for these patients 
included sputum tests, PPD, excision biopsy and histology.  
 
5.9.3  Tuberculosis of the tonsil 
 
These were all female patients between twenty five and thirty five years old. These 
patients presented with discomfort, sore throat, dysphagia, hoarseness, otalgia and 
cough. One patient presented with associated lymph node. Investigations included 
excision biopsy and histology. 
 
5.9.4  Tuberculosis otitis media  
 
The two patients that presented with TB in this region were a forty five year old male 
and a fifty year old female patient. Both patients presented with otalgia, one suffered 
from hearing impairment and deafness and the other had a discharge from the ear. The 
female patient also had TB of the left mastoid and had to have a mastoidectomy 
performed. Chest x-rays, pus culture, excision biopsy and histology were included in 
the investigations.  
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5.9.5  Tuberculosis of the Parotid 
 
This was found in a fifty year old male patient. The patient presented with a lump in 
the neck region and had an excision biopsy and histopathological examination done to 
confirm TB.  
 
5.9.6  Tuberculosis of the nose  
 
The presenting signs and symptoms for this forty two year old male patient were 
headaches and pain in the nasal passage. Investigations included an excision biopsy 
and histopathological examinations. Two patients, a forty one year old female and a 
sixty one year old male presented with TB in the ethmoid sinus. Presenting signs and 
symptoms included otalgia, hoarseness, odynophagia, dysphagia, nose block, 
bleeding, sneezing, headaches and phlegm. Chest x-rays, excision biopsy, and 
histopathological examination were the investigations that were performed.  
  
5.10  CONCLUSION 
 
The analysis of the results was described in this chapter. A major proportion of the 
information such as presenting signs and symptoms and treatment administered was 
not recorded on the cards. This was especially common in the data obtained from the 
surgeons. These patients were transferred back to their referring doctors for further 
management.  
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CHAPTER 6: DISCUSSION 
 
This chapter discusses the findings of the present study. The study was not a 
prevalence study as originally planned, but rather a descriptive study - one of a 
sample of patients with head and neck TB from private practices in the Durban area 
over a fourteen month period.  
 
The causes for the resurgence of TB worldwide vary from one country to another and 
include: co-existing HIV infection, multidrug resistance, failure to comply with 
treatment, social disruption due to war and economic migration and economic poverty 
(Menon et al. 2007). About two thirds of the population in South Africa are infected 
with TB. South Africa was ranked fifth among the world’s twenty two high-burden 
TB countries by the WHO. The national incidence rate was an alarming 718/100 000 
in 1998 (Erstad, 2006).  
 
Three risk factors were identified for extra-pulmonary TB: being female, being 
African (Black) and being HIV positive. The observation made that females are an 
independent risk factor for having extra-pulmonary TB is contrary to the traditional 
understanding that females are more resistant to TB than males. The observation was 
based mainly on animal studies and the reported global sex-difference in TB case 
rates (i.e. in general, a higher proportion of TB case notifications worldwide are for 
male than for female patients). The lower notification rate for females does not 
necessarily mean that females are more resistant to TB than the males, but may be the 
result of under diagnosis or underreporting of TB in females as a result of various 
social and or cultural factors, including the stigmatization of females with TB and 
their consequent impaired access to health care. This situation is often seen in 
developing countries (Yang et al. 2004). Few studies in the past have specifically 
focused on a comparison of extra-pulmonary TB among males with extra-pulmonary 
TB among females. The fact that a biased distribution of any particular type of extra-
pulmonary TB that affects only women was not observed, the biological credibility of 
the finding that being female is strongly associated with extra-pulmonary TB remains 
to be determined through further investigations.  
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There have been reports of an association between non-Hispanic black race and extra-
pulmonary TB in earlier studies of HIV infected subjects (Yang et al. 2004). The 
applicability of these results to other populations is uncertain. This association needs 
confirmation.  
 
The present study included both HIV positive and HIV negative patients with extra-
pulmonary TB. HIV infected patients are more vulnerable to transmission of 
mycobacterium from others with active TB, and those with latent disease have a high 
risk of reactivation. The incidence of TB is about a hundred times more in HIV 
infected patients than that of the general population. Therefore the diagnosis of TB 
lymphadenopathy must be seriously considered in all HIV infected patients who 
present with an enlarging neck mass (Lee and Schecter, 1995).  
 
In the present study, extra-pulmonary TB was found to be more common in the thirty- 
one to forty-year-age group and this is similar to that reported by Yang et al. (2004) 
whose study consisted of a total of 705 patients diagnosed with tuberculosis. 
 
Cervical lymph nodes have been reported to be the most common site in the head and 
neck region to be affected by TB (Prasad et al. 2007; Nohrstrom et al. 2007; Munck 
and Mandpe, 2003). This finding is supported by the present study. The most 
commonly involved cervical lymph nodes could not be identified as the specific sites 
were not recorded on all the patient records but more generalised terminology was 
used. In this study, the clinical presentations of the lymph nodes included discreet 
cervical lymph node swelling, matting, ulcerations and discharge. TB of the head and 
neck lymph nodes was slightly higher on the right side.  
 
The second most common presentation was the tonsils. There is a paucity of literature 
on TB of the tonsils due to the fact that it is exceedingly rare. Reasons for this include 
the fact that tonsillar TB was common at the beginning of the century and was related 
to M. bovis infections acquired by drinking infected milk – with the advent of the 
pasteurization of milk this entity is now extremely rare (Munck and Mandpe, 2003). 
TB of the tonsils was fairly common in the pre-antibiotic era (Waldman, 1982).  
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Prior to the antibiotic era, laryngeal TB was considered to be the most common 
disease of the larynx that was seen in more than a third of patients with pulmonary 
TB. The disease is fairly rare today and occurs in less than 1% of tuberculosis cases 
(Munck and Mandpe, 2003). Patients present with hoarseness, dysphagia, cough and 
discomfort in the throat. Laryngeal TB should be considered in any patient with 
unexplained hoarseness, weakened voice, and pain with swallowing which may 
radiate to the ear as well as odynophagia. Laryngeal TB may involve any site 
including the vocal cords, ventricular bands and epiglottis.  
 
Tuberculous otitis is the next most common form of TB in the head and neck after TB 
of the larynx (Sierra et al. 2000). Aural TB is uncommon and difficult to diagnose 
because the disease presents like other chronic suppurative otitis media. Typical 
features include painless otorrhoea; central perforation; pale, abundant middle ear 
granulations; severe conductive or profound hearing loss; and facial palsy. Bone 
necrosis and sequestration in the mastoid are also common findings. With super-
imposed infection there may be otalgia, foul smelling infection and acute mastoid 
infection and fistulisation. (Prasad et al. 2007). In this study eight patients presented 
with otalgia, two with hearing impairment and two with discharge from the ear. 
Infection of the mastoid process was reported in one patient.  
 
Tuberculosis of the oral cavity was not reported in the sample of the present study.  
 
The definitive diagnosis for the majority of the patients was established by 
histological examination. Tissues should be sent for histological examination to make 
a final diagnosis, if the index of suspicion is high and all other tests for TB are 
negative.  
 
More than two thirds of the patients in this study were transferred for further 
treatment to their referring doctors and therefore the treatment provided for TB was 
not recorded. Treatments that were recorded included Isoniazid, Rifampicin, 
Pyrazinamide and Ethambutol. This is in keeping with the recommended treatment 
regime. Patients that were HIV positive were referred for highly active antiretroviral 
therapy (HAART). There were no follow-ups recorded for these patients; therefore 
the outcomes from the treatment could not be established.  
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CHAPTER 7: CONCLUDING REMARKS 
 
Tuberculosis is a challenging disease and is on the increase. TB of the head and neck 
remains an important diagnosis. It may not be as rare as once thought and is the 
commonest site of extra-pulmonary TB. The diagnosis is often misdiagnosed. A high 
index of suspicion of TB is important in the differential diagnosis of slow-to-heal 
wounds, undiagnosed neck lumps, hoarseness and otorrhoea and especially in HIV 
positive patients with any enlarging neck mass. A biopsy is usually necessary for 
diagnosis. Successful outcome depends upon appropriate chemotherapy and timely 
surgical intervention when necessary. It is in the best interest of the oral health care 
worker to be fully cognizant of all the various presentations of head and neck TB.  
 
A high index of suspicion can help direct investigations, allowing early diagnosis and 
quick commencement of appropriate treatment. TB positive patients should be treated 
in consultation with a physician. Oral health care workers must understand the 
medical management of TB. With the rising incidence of TB, especially in South 
Africa, it is likely that they will be confronted with patients at risk for TB and those 
patients who have been or who are already on anti-tuberculosis therapy.  
 
The cornerstone for the effective control of TB is the effective treatment of persons 
who have active TB. Oral health care facilities have the opportunity for TB screening, 
which as yet, has not been tapped in to its fullest extent in a developing country 
setting like South Africa where TB is endemic. Oral health care workers can play a 
role in this control by identifying patients who may need TB treatment or prophylaxis 
and referring those patients for medical evaluation. TB infection control policies 
should be developed for each dental setting based on risk assessment. This should 
include a review of the community TB profile, which can be obtained from the 
Department of Health, and the number of the TB patients treated in the facility.  
 
Five risk categories are defined: minimal, very low, low, intermediate and high risk. 
High risk settings are those in which there has been evidence of transmission of TB 
(Cleveland et al. 1995).  
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Following risk assessment, policies developed should include provisions for detecting 
and referral of patients with active TB who require urgent dental care. They should 
also include provision for education, counselling and screening of oral health care 
workers. Routine assessment of all dental patients should include whether patients 
have a history of TB and signs and symptoms suggestive of TB.  
 
For oral health care facilities that provide care to populations at high risk for TB, 
controls to decrease the risk of transmission should be considered: ventilation and air 
flow considerations, such as high-efficiency particulate air filters or ultraviolet 
germicidal irradiation (CDC, 1998). Use of disposable tubes and masks for nitrous 
oxide sedation to prevent patient-to-patient transmission, TB positive patients should 
be scheduled for morning or late in the afternoon appointments to reduce the 
possibility of patient-to-patient transfer in the waiting areas.  
 
While the risk of TB transmission in the oral health setting is probably low, the 
consequences of exposure can be substantial. Oral health care workers have a duty to 
take appropriate precautions to protect themselves, their staff and their patients from 
the risk of cross infection. The implementation of infection control policies is critical 
to the provision of such protection.  
 
Oral health care workers must be knowledgeable about the potential risks of 
occupation exposure, the importance of practicing universal infection control and 
post-exposure management strategies for those potentially exposed to TB. A clear, 
written TB infection control protocol should promote the importance of surveillance 
in the oral health setting. Referral and integration of TB screening in high HIV and 
TB prevalence areas will provide early diagnosis, treatment of TB and possibly 
prevention and reduced risk of nosocomial infection. 
 
At present there are no specific guidelines for infection control for South Africa. 
Guidelines need to be actively promoted and established. These guidelines need to be 
pertinent to South Africa and must be flexible enough to fit individual circumstances.  
Recommendations should be based on available resources and be sensitive to the 
powerful social, political and psychological forces behind the public and professional 
response to the TB pandemic. 
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As noted in the introduction to this thesis, HIV increases the susceptibility of the HIV 
positive person to TB. Educating communities and patients to recognise symptoms of 
TB and to seek health care and further investigations should be routine in all settings 
providing care for patients, especially HIV-infected persons. Coordination and 
communication between HIV and AIDS and TB programmes must be prioritised.  
 
There is much information on TB in South Africa and there should not have been the 
limitations to the gathering of the study data. The problems experienced could have 
been avoided if patient data was properly recorded and easily accessible to 
researchers. It is recommended that information systems be improved for easy 
identification of specific conditions, doctors should keep proper, legible and 
comprehensive notes for their patients and that all data should be accessible to bona-
fide researchers particularly in the public sector hospitals.  
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APPENDIX 1: DATA CAPTURE SHEET 
 
1. Patient no. 
 
2. Age:  
 
3. Gender: Male Female 
 
4. HIV/AIDS (confirmed): Yes  No 
 
Presenting signs and symptoms 
 
 
Condition Yes No Not recorded 
5 Fever   
6 Weight loss    
7 Cough    
8 Hoarseness   
9 Odynophagia   
10 Dysphagia    
11 Otalgia   
12 Other: 
 
 
 
 
Type of examinations and investigations 
 
 
Investigations Yes No Not Recorded  
13 Needle aspiration cytology   
14 Chest x-ray    
15 Sputum culture    
16 Purified protein derivative 
(PPD) 
  
17 Pus – culture & sensitivity   
18 Excision biopsy    
19 Histopathological examination   
20 Other: 
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Head and Neck sites of tuberculosis  
 
 
Location Yes No Not recorded 
21 Lymph nodes 
Specify: 
  
22 Tonsil    
23 Larynx   
24 Cervical spine   
25 Parotid glands   
26 Tongue   
27 Hard palate    
28 Soft palate   
29 Mandible   
30 TMJ    
31 Maxilla   
32 Nose   
33 Tubercular otitis media   
34 Buccal mucosa   
35 Gingiva   
36 Floor of mouth   
37 Lips   
 Other:  
 
 
 
Other sites  
 
 
Location Yes No Not recorded 
38 Lung   
39 Brain   
40 Spine   
41 Abdomen   
42 Skeletal   
43 Liver   
 Other:  
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Treatment provided  
 
 
Treatment Yes No Not recorded 
44 Chemotherapy   
45 Isoniazid    
46 Rifampicin   
47 Pyrazinamide   
48 Ethambutol   
49 ART   
50 Surgery    
51 Radiotherapy   
 Other:  
 
 
 
 
Outcomes  
 
 
Outcome Yes No Not recorded 
52 Survived in remission   
53 Recurrence    
54 Lost to follow up    
55 Died   
56 Defaulted   
57 Treatment Failed    
58 Transferred   
59 Cured   
60 Not evaluated   
 Other: 
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APPENDIX 2: CONSENT TO ACCESS RECORDS AND TO CARRY OUT 
RESEARCH STUDY 
 
INFORMATION SHEET  
 
TO WHOM IT MAY CONCERN 
 
I, Ms M Reddy, am a Dental Therapist working at the Oral and Dental Training 
Centre. At present I am studying part time and am currently a Masters student at the 
Department of Community Dentistry, University of Western Cape.  
 
The resurgence of TB as a public health problem has rekindled interest in this disease 
among oral health workers (OHW). However, much research has focused on 
pulmonary and extra-pulmonary TB involving the abdomen and spine and there is a 
paucity of literature on the head and neck region. Extra-pulmonary presentations form 
a major proportion of new cases concomitant with HIV epidemic. Systemic symptoms 
may be absent and oral lesions may be the first manifestation of the disease. Therefore 
oral health workers need to be aware of TB in the head and neck region and it’s varied 
manifestations. 
 
For my research project, I have undertaken to do a retrospective record-based study 
on the prevalence of head and neck tuberculosis in Durban over a twelve year period 
to determine the presentation of head and neck tuberculosis and describe it’s 
management. This study has not been carried out in Durban before. It is important and 
will be of great value to the medical and dental profession regarding early diagnosis 
and management. 
  
In order to be able to carry out this study I will need access to patient records. All 
information gathered in the study will be treated as strictly confidential. No one will 
have access to this information except me, the principal investigator. No names will 
be used in the reports of this study. All information collected will be maintained and 
stored in such a way as to keep it as confidential as possible. 
 
If you have any questions or queries regarding the proposed study please do not 
hesitate to contact me, Ms M Reddy on Tel: 031-2426214 work, 031-2628623 home, 
cell: 084 584 4288.  
 
Thanking you in advance for your co-operation. 
 
Yours sincerely 
 
 
 
_______________________________ 
Ms M Reddy 
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APPENDIX 3: ETHICS APPROVAL LETTER FROM THE UNIVERSITY OF 
THE WESTERN CAPE  
 
Department of Community Oral Health 
Faculty of Dentistry & WHO Collaborating Centre for Oral Health 
  
UNIVERSITY OF THE WESTERN CAPE 
Private Bag X1, Tygerberg 7505 
                           Cape Town 
                                 SOUTH AFRICA 
   
25th June 2008 
 
 
TO WHOM IT MAY CONCERN 
 
 
Re: Ms M Reddy - MSc (Dent) in Dental Public Health  
 
This letter serves to confirm that Ms M Reddy is a post-graduate student on above-
mentioned course at the Faculty of Dentistry, University of the Western Cape.  
 
Her student number is 2874099 
 
Her research project has been passed by the Senate Research Ethics Committee of the 
University with the registration number 08/4/11  
 
Should you require any additional information, do not hesitate to contact me on tel: 
27-21-937 3148 (w) 686 2720 (h); fax: 27-21-931 2287 or email: 
suenaidoo@uwc.ac.za.  
 
 
Yours sincerely 
 
 
 
 
Professor Sudeshni Naidoo 
Course Co-ordinator 
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APPENDIX 4: APPROVAL LETTER FROM KING GEORGE V HOSPITAL 
 
 
 
 
 DEPARTMENT OF HEALTH 
     PROVINCE OF KWAZULU-NATAL 
 
                    KING GEORGE V HOSPITAL 
PO DORMERTON,4015 
75 STANLEY COPLEY DRIVE, SYDENHAM, DURBAN 
 
Enquiries:  Dr S Maharaj 
            
 
Telephone Number:    
(031) 2087121 Ext:  356 
 
Fax Number:   (031) 2099586 
 
                    
Email:shamin.mahraj@health.gov.za  
 
Your Reference           :   
                      
 
Date:   30 June 2008                
 
 
For Attention: Ms M Reddy 
Post Graduate Student 
University of Western Cape 
 
Dear Ms M Reddy 
REQUEST FOR PERMISSION - ACCESS TO PATIENT INFORMATION 
AT KING GEORGE V HOSPITAL 
 
1. Your letter dated 30 June 2008 refers. 
 
2. Permission is granted for the above mentioned purpose. Please find attached 
copy of indemnity form for completion and submission by yourself prior to 
undertaking the study. 
 
3. Your attention is once again drawn to the maintenance of confidentiality as 
discussed. 
 
4. Arrangements should be made for you to work with patient files and staff in 
the MDR TB Department.   
 
 
DR S B MAHARAJ 
MEDICAL MANAGER 
 
APPENDIX 5: APPROVAL LETTER FOR RESEARCH PROPOSAL – 
DEPARTMENT OF HEALTH 
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